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1. INTRODUCTION 
 
Cancer is the leading killer in the United States, surpassing heart disease in 2004. 
According to the American Cancer Society, more than 1,500 people die each day 
from cancer and over 16 million people have been diagnosed with cancer since 
1990. 
In recent years, medical science has taken great strides in understanding and 
treating cancer. However, prior to 1997, the majority of treatments such as 
chemotherapy and radiation, were not based on the underlying biology of cancer 
growth. These treatments are also often associated with serious side effects. 
Cancer is the result of oncogenic transformation of normal cells to produce cells 
which have the potential for uncontrolled division, producing a tumour cell mass 
which invades and  destroys the tissue in which it arose, and has the potential to 
metastatize. It is now recognized that oncogenic transformation is the result of 
genetic mutations  affecting systems controlling the cell cycle and cell death. This 
has implications for the way in which anti-cancer therapies are developed, because 
the identification of factors or pathways that are altered in cancer cells may allow the 
development of specific therapies that target these changes (Hortobagyi, 1999).  
Growth factors act by binding to cell surface receptors and activating pathways that 
result in the expression or inhibition of proteins that control cell function. In contrast, 
tumour suppressor genes are involved in the control of programmed cell death 
(apoptosis) and prevent uncontrolled proliferation. The balance between the 
expression of proto-oncogenes and tumour suppressor genes is critical if tissues 
have to grow and be maintained normally. Research has shown that a series of 
mutations in these genes is at least partially responsible for the progression from 
normal breast epithelium to breast cancer and the maintenance of the malignant 
phenotype (Aaronson, 1991, Harris, 1992). Genes that have been implicated in the 
pathogenesis of breast cancer include c-myc (Escot, 1986), H-ras (Agnantis, 1986), 
hst (Lidereau, 1988), int2 (Lidereau, 1988), p53 (Cossman & Schlegel, 1991, 
Kovach, 1991) and the human epidermal growth factor receptor (HER) gene family 
(Benz ,1992, Chazin, 1992). 
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1.1. THE HER FAMILY 
 
The HER family comprises four genes encoding four homologous ErbB or type I 
tyrosine kinase receptors: epidermal growth factor receptor (ErbB1, EGFr or HER1), 
ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4) (Pinkas- Kramarski, 1997). 
The various naming systems for these genes are the result of the discovery of 
homologous genes involved in the pathogenesis of erythroblastoma in chickens 
(erbB) (Vennstrom and Bishop, 1982) and of genes encoding growth factor receptors 
in humans (HER). However, HER is the most commonly used designation.  
The HER receptors are located at the cell membrane and share similar structure, 
comprising an extracellular growth factor binding domain, a lipophilic transmembrane 
domain and an intracellular protein kinase domain with a regulatory C-terminal 
segment  (van der Geer, 1994). 
A physical feature of the HER pathway is that the signaling system always involves 
two receptors in combination (dimer): homodimers are combinations of two similar 
receptor types, heterodimers contain two different receptors The various hetero- and 
homodimer pairs affect the signal strength within the cell. For example, the co-
expression of certain pairs (such as HER3/HER2) is more powerful than others such 
as the HER3/HER-3 homodimer, which is inactive. 
 
1.1.1. STRUCTURE AND FUNCTION OF HER2 
 
The HER2 gene is located on the long arm of chromosome 17 (Coussens, 1985). 
Normal cells contain two copies of the HER2 gene, which encodes a protein 
comprising 1255 amino acids of molecular weight 185 kDa (Akiyama, 1986). This 
protein has homology to, and conforms with, the general structure of the HER 
proteins (Coussens, 1985, Hynes & Stern, 1994). 
HER2 and the three other members of the HER family are transmembrane tyrosine 
kinase receptors with growth-stimulating activity. Tyrosine kinases are enzymes that 
transfer phospho-groups from adenosine triphosphate to tyrosine molecules in 
proteins, resulting in their activation. Activation of HER receptors ultimately results in 
nuclear gene activation. 
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1.1.2. HER2 ACTIVATION 
 
HER2 activation is usually dependent on the presence of small molecules called 
ligands (Akiyama, 1988, Kokai, 1989) and other HER receptors (Connelly & Stern, 
1990). The ligands involved in HER2 activation include epidermal growth factor 
(Akiyama, 1988) and neuregulins (Plowman, 1993), which interact specifically with 
HER receptors. However, it appears that these ligands can activate HER2 only when 
it is associated with HER1, HER3 or HER4 in the form of a heterodimer (Alroy & 
Yarden, 1997, Lemmon & Schlessinger, 1994). Infact, while no known specific ligand 
for the HER-2 receptor has been identified, evidence indicates that HER2 is the 
preferred heterodimerization partner within the HER family (Graus-Porta, 1997) and 
that HER2-containing heterodimers have particularly high ligand-binding potency 
(Sliwkowski, 1994). Furthermore, the effect of the binding of ligands to HER 
heterodimers varies depending on the specific molecules involved (Hynes & Stern, 
1994), i.e. the effect of epidermal growth factor binding to a HER1-HER2 heterodimer 
may differ from that of neuregulin binding to a HER2-HER3 heterodimer. Therefore, 
the interactions between HER2 and the other HER proteins and the activity of the 
various known ligands are important to the complex processes controlling cell growth 
and differentiation. 
 
1.1.3. NORMAL BIOLOGICAL FUNCTION OF  HER2 
 
HER2 is expressed in many cell types outside the haematological system, including 
nervous system, bone, muscle, skin, heart, lungs and intestinal epithelium 
(Coussens, 1985). Expression levels are higher in foetal tissues than adult tissues 
(Press, 1990). The activity of the HER2 protein in these tissues is affected by which 
ligands and other HER receptors are present. For example, HER1 and HER2 are 
often co-expressed and neuregulins and EGF-like ligands are known to be able to 
activate HER2 in an autocrine and paracrine fashion (Marchionni, 1993). The activity 
of HER2 has been most widely studied in breast cancer cell lines. Studies have 
demonstrated that EGF-like ligands and neuregulins can inhibit or stimulate cell 
proliferation depending on the cell line tested (Peles, 1992, Lewis, 1993 a)), with 
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some growth-inhibited cells having the characteristics of differentiated breast 
epithelial cells (Peles, 1992). 
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1.2.  ROLE OF HER2 IN CANCER 
 
The role of the HER receptors in controlling cell growth and the importance of HER2 
as a heterodimerization partner suggest that HER2 may have a critical role in the 
development of cancer. 
 
1.2.1. HER2 AMPLIFICATION/ OVEREXPRESSION IN HUMAN TUMOURS 
 
Studies of human cancers have demonstrated that HER2 gene amplification (on 
17q12 chromosome) and/or HER2 receptor overexpression are observed in a variety 
of tumour types. Such tumour types include breast (Slamon, 1989, Berns, 1992), 
ovarian (Slamon, 1989, Hynes & Stern, 1994), pancreatic (Lei, 1995) and lung 
cancer (Weiner, 1990, Kim, 1998). The data from studies of cell lines and animal 
xenograft models suggest that these findings are not incidental, i.e. HER2 
amplification/overexpression is involved in malignant transformation rather than being 
a marker of cancer cells that has no role in their production. 
HER2 amplification/ overexpression has been detected in varying proportions of a 
range of human cancers. The percentage of tumours in which the HER2 gene is 
amplified is usually lower than the percentage in which the protein is overexpressed. 
The incidence of HER2 gene amplification is 25±30% for breast and 15±30% for 
ovarian carcinomas, with the incidence of HER2 protein overexpression being slightly 
higher (Slamon, 1987, 1989). 
In vitro studies of HER2 overexpression in breast cancer cells indicate that HER2 
gene amplification occurs in 92% of breast cancer specimens overexpressing the 
HER2 receptor (Pauletti, 1996). The role of HER2 receptor overexpression in the 
absence of gene amplification is unknown. It also appears that gene amplification is 
distinct from aneuploidy or the presence of multiple copies of the normal 
chromosome complement of a cell: breast cancers containing aneuploid cells with 
multiple copies of chromosome 17 behave similarly to cancers with normal HER2 
gene copy numbers. 
It has been demonstrated that HER2 gene amplification is an early event in the 
development of cancer (Chong, 1999). In this study, sections of pure ductal 
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carcinoma in situ (DCIS), DCIS associated with invasion and invasive tumours were 
analysed using a sensitive radiolabelling technique. This revealed that the frequency 
distribution of HER2 expression was similar in DCIS and DCIS with invasion and in 
DCIS with invasion and invasive cancer. Furthermore, HER2 expression levels were 
similar in the DCIS and invasive components of DCIS with invasion. Others have 
shown that HER2 amplification/overexpression is strongly associated with the poorly 
differentiated type of DCIS, which is more likely to progress to invasive breast cancer 
(Barnes, 1992, Liu, 1992). 
 
1.2.3. HER2 AND ONCOGENIC TRANSFORMATION 
 
As stated above, HER2 amplification/overexpression is associated with DCIS and 
invasive breast cancer. However, HER2 amplification/ overexpression is not 
observed in normal breast cells, proliferative disease without atypia and proliferative 
disease with atypia. Therefore, HER2 amplification and cell transformation occur at 
approximately the same time. However, it appears that oncogenic transformation 
usually begins with an unknown initial event. If breast cancer cells are transfected 
with the HER2 gene, they become fully transformed and exhibit aggressive growth 
characteristics (Benz, 1992, Chazin, 1992). In contrast, normal breast cells are not 
affected by HER2 gene transfection. This indicates that oncogenic transformation is 
at least a two-stage process involving an initiating event followed by HER2 gene 
amplification, which occurs for as yet unknown reasons. 
HER2 gene amplification results in epidermal cells containing more than the normal 
two gene copies. For practical purposes, five gene copies per cell may be considered 
as an appropriate cut-off point for defining gene amplification (Liu, 1992). When the 
HER2 gene is amplified, HER2 mRNA levels and ultimately HER2 protein levels are 
increased. HER2 protein is then overexpressed on the cell surface at levels 10- to 
100-fold greater than normal (Venter, 1987). This appears to result in the formation of 
HER2 homodimers, which are probably active without the need for ligand binding. 
This abnormal activity results in unregulated cell growth, in some instances resulting 
in cancer (Di Fiore,1987, Hudziak, 1987). 
The overexpressed HER2 gene product is usually normal (Pauletti, 1996), i.e. it is 
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identical to the HER2 receptor found in normal cells. No mutational changes in the 
HER2 protein in human cancers have been reported (Aaronson, 1991). 
Thus, in the majority of cases the presence of increased numbers of the HER2 gene 
results in overexpression of structurally normal HER2 protein (Hynes & Stern, 1994). 
It is possible that abnormalities of the control of HER2 mRNA formation or translation 
to produce protein are the cause of HER2 mRNA or receptor overexpression in 
tumours in which HER2 gene amplification is not present (Slamon, 1989). 
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1.3. HERCEPTINTM THERAPY 
 
1.3.1.  DEVELOPMENT OF HERCEPTINTM 
 
Murine monoclonal antibodies (muMAbs) can be generated to target a specific 
antigenic determinant on a protein. muMAbs directed against the extracellular 
domain of the HER2 receptor inhibit proliferation of monolayer cultures of breast and 
ovarian tumour cells overexpressing HER2 (Hudziak, 1989, McKenzie, 1989). 
 The antibody designated muMAb 4D5 was found to be particularly potent and was 
selected for further clinical  development.  
In clinical practice muMAbs have limited use because the human immune system 
recognizes murine antibodies as foreign and develops an immunogenic response to 
them (Miller, 1983).  
Using recombinant technologies, trastuzumab (HerceptinTM), a monoclonal IgG1 
class-humanized murine antibody, was developed by Genentech (South San 
Francisco, CA) to specifically bind the extracellular portion of HER2. HerceptinTM is 
95% human and 5% murine and demonstrates a higher binding affinity for the 
extracellular domain of HER2 than muMAb 4D5  (Lewis, 1993 b)). 
This antibody therapy was initially targeted specifically for patients with advanced 
relapsed breast cancer that overexpressed the HER2/neu protein (Huston, 2001). 
Since its launch in 1998, trastuzumab has become an important therapeutic option 
for patients with HER2-positive breast cancer. 
The addition of trastuzumab to chemotherapy (either anthracycline plus 
cyclophosphamide or taxane) was associated with a longer time to disease 
progression, a higher rate of objective response, a longer duration of response, a 
lower rate of death at 1 year, longer survival, and a 20% reduction in the risk of death 
(Slamon, 2001). Although not completely understood at this time, mechanisms 
believed to be associated with the anti-tumour effects of trastuzumab include ADCC 
(antibody depended cytotoxicity), immune system mediated prevention of HER2 
dimerization with reduced or interrupted downstream  signalling, and so on (Nahata, 
2003). 
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1.3.2. PREDICTING RESPONSE TO THERAPY 
 
HER-2 STATUS AND THE PREDICTION OF RESPONSE TO TRASTUZUMAB 
THERAPY. 
The best method to identify patients who may respond to trastuzumab therapy has 
been a source of controversy. The original IHC technique used in the trastuzumab 
pivot trial was succeeded by two commercially available HER2 IHC kits, the Dako 
HerceptestTM and the Ventana PathwayTM, both FDA-approved, but, after its approval 
and launch, the HerceptestTM assay was criticized for yielding false-positive results.  
Concern over IHC accuracy using standard formalin-fixed paraffin-embedded tissue 
sections has encouraged the use of the FISH (Fluorescence in Situ Hybridazation) 
assay for its ability to predict trastuzumab response rates. Two versions of the FISH 
assay are FDA-approved; the Ventana InformTM test that measures only HER2 gene 
copies and the Abbott-Vysis PathvysionTM test that includes a chromosome 17 probe 
in a dual colour format. In a recently published study where trastuzumab was used as 
a single agent, the response rates in  patients with 3+ IHC staining was 35% and the 
response rates for 2+ cases was 0%; the response rates in patients with and without 
HER-2/neu gene amplification detected by FISH were 34 and 7%, respectively 
(Vogel, 2002). Similar results were obtained in another study of breast cancer treated 
with trastuzumab plus paclitaxel, in patients with HER2 overexpressing tumours.  
Other recent studies have favoured the FISH approach not only to confirm 2+ IHC 
cases but to also confirm 3+ and prevent the use of potentially toxic trastuzumab to 
patients with false-positive IHC results who are unlikely to benefit from this therapy 
(Hammock, 2003). 
So it can be concluded that gene amplification plays an important role in the 
progression and initiation of breast cancer, as amplification and consequent 
overexpression of HER2 oncogene is  found in 10-34% of primary human breast 
tumours and is associated with poor clinical outcome (Ross, 1998). So HerceptinTM 
has been successfully used for treatment of patients with advanced breast cancer, 
but not all patients with HER2 receptor overexpression, if  not associated with gene 
amplification, respond favourable to HerceptinTM  therapy.  
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1.4.  HER2 AMPLICON ON HUMAN CHROMOSOME 17q12 
 
These recent discoveries have directed further interest toward HER2 oncogene, 
especially to the identification of additional genetic factors that might influence the 
treatment responses of HER2-positive tumours. Several genes, located adjacent to 
HER2, have been shown to be frequently amplified and overexpressed together with 
HER2 indicating that the 17q12 amplification leads to simultaneous activation of 
multiple genes. These co-amplified and overexpressed genes might be likely 
candidates for factors that have an impact on the treatment responses observed in 
the HER2-amplified tumours (Kauraniemi, 2003).  
It has been performed a detailed characterization of the structure of the HER2 
amplicon in breast cancer cell and it has been defined a minimal common region of 
amplification at 17q12, restricted to a less than 0.5-Mb region around the HER2 locus 
(Kauraniemi, 2001). They next showed that expression levels of most of the genes 
located in this minimal common region of amplification were elevated. Although 
several studies have illustrated that genetic aberrations observed in cell-line model 
systems are highly representative of those occurring in primary tumours, it is 
essential to confirm results obtained from such model systems in primary tumours. 
Such confirmation is especially relevant in the case of amplicons because previous 
studies have suggested that the size of amplicons decreases as a function of time. 
The initial amplicons are thought to be large but during subsequent cell cycles, 
progressively smaller regions are selected for leading to a reduction in the amplicon 
size (Stark , 1989).  
The 17q12 amplicon, as shown in a large set of primary breast tumours, has a core 
region of amplification spanning only 280 kb. The minimal common region of 
amplification at 17q12 contains a total of 10 transcripts (ERBB2, GRB7, MLN64, 
PNMT, NEUROD2, ZNFN1A3, TCAP, PPP1R1B and  two hypothetical proteins 
MGC14832 and MGC9753), including the HER2 oncogene. Quantitative real-time 
RT-PCR analysis revealed that only six of these transcripts showed a strong 
statistically significant correlation between amplification and expression levels 
indicating that increased gene copy number does not inevitably lead to elevated 
expression. In addition to HER2, expression levels of five other genes, GRB7, 
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MLN64, PNMT, MGC9753, and MGC14832, were consistently elevated in tumours 
with amplification (Kauraniemi, 2003).  
The fact that amplification leads to elevated expression of several but not all genes 
within an amplicon argues against the traditional concept in which there is a single 
target gene for each amplicon. However, it cannot be directly assumed that all of 
these genes with elevated expression levels would have important and independent 
roles in tumorigenesis. It is indeed possible that increased expression of a particular 
gene represents a simple by-product of co-amplification and does not confer any 
advantage for the cancer cell. However, it is also possible that the coordinated effect 
of deregulated expression of several genes is essential for the selective growth 
advantage of the tumour cells.  
The GRB7 and MLN64 genes have been previously shown to be co-amplified and 
overexpressed with HER2 (Tomasetto, 1995) and, based on their function, increased 
expression of these genes might be important for cancer pathogenesis.  
GRB7 codes for a SH2 domain-containing growth factor receptor tyrosine kinase that 
has been shown to function in cell migration, thus suggesting a possible role for 
GRB7 in metastasis.  
MLN64 shares significant homology with the steroidogenic acute regulatory protein 
and it has been proposed to facilitate steroid hormone production in cancer cells.  
Although statistically associated with gene amplification, the expression levels of 
PNMT were rather low and not consistently elevated in the amplified tumour group, 
therefore decreasing its relevance as a putative cancer gene. 
On the contrary, the hypothetical proteins MGC9753 and MGC14832 showed highly 
significant association between gene amplification and expression levels. 
Unfortunately, their sequence shows no similarity to any currently known genes or 
proteins, therefore leaving their function and possible role in cancer unresolved.  
The potential contribution of two hypothetical proteins, MGC9753 and MGC14832, to 
the development and progression of breast cancer or to the clinical behaviour of 
HER2-amplified tumours needs to be evaluated.  
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Physical map of the 17q12-q21 region. Schematic representation of the 280-kb minimal region of 
amplification located between clones 390P24 and 387H17. Transcripts mapping to the minimal region 
are represented with arrows and their orientation is indicated. The maps were not drawn in scale. 
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1.5. HER2 AMPLICON ON MOUSE CHROMOSOME 11. 
Mouse Ppp1r1b, Stard3, Tcap, Pnmt, Mgc9753, Erbb2, Mgc14832, and Grb7 genes 
were located around the synthenic locus on mouse chromosome 11, corresponding 
to the PPP1R1B-GRB7 locus on human chromosome 17q12. Mouse Ppp1r1b-Grb7 
locus and human PPP1R1B-GRB7 locus were evolutionarily conserved in the order 
and the orientation of genes therein (Katoh & Katoh,  2003). 
 
Comparative genomics on the PPP1R1B-GRB7 locus. A, schematic presentation around the 
mouse Ppp1r1b-Grb7 locus. Mouse genome around the Ppp1r1b-Grb7 locus is shown by bold 
horizontal bar, while mouse genes are shown by an arrow with gene symbol.  Mouse Ppp1r1b-Grb7 
locus and human PPP1R1B-GRB7 locus were evolutionarily conserved in the order and the 
orientation of genes therein. B, comparative genomics on the Ppp1r1b-Grb7 locus. Gene symbol, 
alias, and function of genes around the Ppp1r1b-Grb7 locus are shown. Coding region nucleotide 
substitution rate and amino-acid substitution rate between human and mouse orthologs around the 
Ppp1r1b-Grb7 locus are also shown 
Mouse Erbb2 gene, consisting of 27 exons, was located, in the forward orientation, 
between the mouse Mgc9753 gene, in the reverse orientation, and mouse Mgc14832 
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gene, in the reverse orientation too,  within the Ppp1r1b-Grb7 locus on the mouse 
chromosome 11. Mouse Erbb2 protein (1256 aa) showed 87.5 and 95.2% total 
amino-acid identities with human ERBB2 and rat Erbb2 proteins, respectively.  
 
 
 
Comparative genomics of the oncogenomic recombination hotspot around the PPP1R1B-PERLD1-
ERBB2-GRB7 amplicon (grey box) on human chromosome 17q12-q21 and mouse chromosome 11D. 
 
 
 
 
 
 
 
 
 
 
 
 
 15
1.6. OXIDATIVE STRESS, ANTIOXIDANT DEFENSES, AND DAMAGE 
REMOVAL, REPAIR, AND REPLACEMENT SYSTEMS 
 
Oxidative stress is an unavoidable consequence of life in an oxygen-rich 
atmosphere. Oxygen radicals and other activated oxygen species are generated as 
by-products of aerobic metabolism and exposure to various natural and synthetic 
toxicants. The “Oxygen Paradox” is that oxygen is dangerous to the very life-forms 
for which it has become an essential component of energy production (Davies, 
2000). 
The 1st defence against oxygen toxicity is the sharp gradient of oxygen tension, seen 
in all mammals, from the environmental level of 20% to a tissue concentration of only 
3–4% oxygen. These relatively low tissue levels of oxygen prevent most oxidative 
damage from ever occurring. Cells, tissues, organs, and organisms utilize multiple 
layers of antioxidant defences and damage removal, and replacement or repair 
systems in order to cope with the remaining stress and damage that oxygen 
engenders. The enzymes comprising many of these protective systems are inducible 
under conditions of oxidative stress adaptation, in which the expression of over 40 
mammalian genes is upregulated. Mitotic cells have the additional defensive ability of 
entering a transient growth-arrested state (in the 1st stage of adaptation) in which 
DNA is protected by histone proteins, energy is conserved by diminished expression 
of nonessential genes, and the expression of shock and stress proteins is greatly 
increased. Failure to fully cope with an oxidative stress can switch mitotic cells into a 
permanent growth-arrested, senescence-like state in which they may survive for long 
periods. Faced with even more severe oxidative stress, or the declining protective 
enzymes and adaptive capacity associated with aging, cells may “sacrifice 
themselves” by apoptosis, which protects surrounding healthy tissue from further 
damage. Only under the most severe oxidative stress conditions will cells undergo a 
necrotic death, which exposes surrounding tissues to the further vicissitudes of an 
inflammatory immune response. This remarkable array of systems for defence, 
damage removal, replacement,  repair, adaptation, growth modulation and apoptosis 
make it possible for us to enjoy life in an oxygen-rich environment. 
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Thankfully, we are not defenceless against the oxygen radical and other activated-
oxygen species to which we are constantly exposed. All aerobic organisms, including 
human beings, utilize a series of primary antioxidant defences in an attempt to 
protect against oxidant damage. 
 
1.6.1. ANTIOXIDANT COMPOUNDS 
 
Our cells utilize a series of antioxidant compounds to directly react with oxidizing 
agents and disarm them (Ozben, 1998); such antioxidants are said to be 
“scavengers”. Vitamin E (α-tocopherol) is a major membrane-bound antioxidant, and 
vitamin C (ascorbic acid) is a major aqueous-phase antioxidant. Other water-soluble 
antioxidant compounds include uric acid, glutathione, and ceruloplasmin; by binding 
iron and/or copper, uric acid may inhibit metal-catalyzed oxidation reactions without 
itself becoming oxidized. Other lipid-soluble agents, including β-carotene and 
ubiquinone, may also play important antioxidant roles in vivo. 
 
1.6.2. ANTIOXIDANT ENZYMES 
 
Aerobic organisms also synthesize numerous antioxidant enzymes and other 
proteins in an attempt to minimize oxidative damage (Fridovich, 1995); the best 
known of these enzymes is superoxide dismutase. The superoxide dismutases 
(SOD) catalyze the reaction O2ֹ־ + O2ֹ־ ?H2O2 + O2 . Genetic deletion of SOD has 
been shown to be a lethal mutation in lower organisms, underpinning the essential 
importance of this enzyme family. The product of SOD is H2O2, which is clearly toxic 
and must be rapidly removed. In mammalian cells this is accomplished by two 
enzyme families: the glutathione peroxidases and the catalases. Both glutathione 
peroxidases and catalases detoxify H2O2 by reducing it to water and oxygen.  
 
1.6.3. TRANSIENT GROWTH ARREST 
 
One of the surprises to emerge from studies of cellular stress responses is the 
observation that transient growth-arrest is utilized by mitotic cells to protect against 
 17
acute stress (Wiese, 1995). Our current understanding or interpretation is that the 
DNA of dividing cells is much more susceptible to damage than is that of postmitotic 
cells. In postmitotic cells, DNA is, for the most part, maintained in a supercoiled state 
and is further protected by a coating of histone proteins. In contrast, the DNA of 
mitotic cells spends long periods of time in an uncoiled state, with no histone protein 
coating, in order to undergo replication. This uncoiled and naked state of DNA in 
dividing cells makes them especially susceptible to various forms of damage, 
including oxidative stress. The situation is further exacerbated by the heavy 
metabolic demands of very high rates of transcription, translation, and the multiple 
processes leading to division in mitotic cells. Thus, an early response of mitotic cells 
to oxidative stress is to enter a transient growth-arrested state in which DNA is 
largely supercoiled, replication is halted, and only a few shock or stress genes are 
transcribed and translated (Wiese, 1995). If the oxidative stress is not severe enough 
to cause apoptosis or necrosis, mammalian cells will re-enter the growth cycle after 
some 3 to 4 h of transient growth-arrest, undergo adaptive changes, and actually 
exhibit increased tolerance to oxidative stress after several hours. 
 
1.6.4. REPAIR SYSTEMS 
 
Damage repair systems may be classified as either direct or indirect (Davies, 1995). 
Direct repair, about which we know only a little, has so far only been demonstrated 
for a few classes of oxidized molecules. Some important direct repair processes are 
the re-reduction of oxidized sulfhydryl groups on proteins, the direct repair of DNA 
hydroperoxides by glutathione peroxidase.  
 
Extensive studies have revealed that oxidized proteins are recognized by proteases 
and completely degraded (to amino acids); entirely new replacement protein 
molecules are then synthesized de novo (Sitte, 2000). It appears that oxidized amino 
acids within oxidatively modified proteins are eliminated or used as carbon sources 
for ATP synthesis. Because an oxidatively modified protein may contain only two or 
three oxidized amino acids, it appears probable that most of the amino acids from an 
oxidized and degraded protein are reutilised for protein synthesis. Thus, during 
oxidative stress many proteins synthesized as damage replacements are likely to 
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contain a high percentage of recycled amino acids. During periods of particularly high 
oxidative stress, the proteolytic capacity of cells may not be sufficient to cope with the 
number of oxidized protein molecules being generated. 
Under such circumstances, oxidized protein may not undergo appropriate proteolytic 
digestion and may instead cross-link with one another or form extensive hydrophobic 
bonds. Such aggregates of damaged proteins are detrimental to normal cell functions 
and lead to further problems. 
In bacteria such as Escherichia coli, a series of proteolytic enzymes act cooperatively 
in the recognition and degradation of oxidatively modified soluble proteins. A similar 
series of proteolytic enzymes appear to conduct the degradation of oxidatively 
modified soluble proteins in mammalian mitochondria. In the cytoplasm and nucleus 
of eukaryotic cells, however, oxidized soluble proteins largely appear to be 
recognized and degraded by the proteasome complex, which constitutes up to 1% of 
total cellular protein.  
Lipid peroxidation was the 1st type of oxidative damage to be studied. Membrane 
phospholipids are continually subjected to oxidant challenges. Peroxidized 
membranes become rigid, lose selective permeability, and under extreme conditions, 
can lose their integrity. Peroxidized membranes and lipid oxidation products 
represent a constant threat to aerobic cells. It is now widely held that in addition to 
preventing initiation of peroxidation (with compounds such as vitamin E), cells have 
also developed a variety of mechanisms for maintaining membrane integrity and 
homeostasis by repairing oxidatively damaged lipid components. 
Ribo- and deoxyribonucleic acids are also vulnerable to oxidative damage, and 
perhaps most importantly, DNA has been shown to incur oxidative damage in vivo 
(Davies, 1995). Although DNA is a relatively simple biopolymer made up of only four 
different nucleic acids, its integrity is vital to cell division and survival. Oxidative 
alterations to nucleic acid polymers has been shown to disrupt transcription, 
translation, and DNA replication, and to give rise to mutations. 
Several eukaryotic glycosylases that act on DNA oxidation products have been 
characterized. A 3’-repair diesterase in yeast is apparently responsible for removing 
damaged 3’ termini left by free radical reactions. A mammalian endonuclease has 
been isolated based on its specificity for oxidatively modified DNA. 
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There is substantial evidence for the vital role of redoxyendonucleases in higher 
eucaryotic cells. DNA damage that appears in cells as a result of an acute oxidant 
challenge (including base damage and single-strand breaks) has been shown to 
diminish as a function of time. These results suggest that a removal of lesions is 
being carried out by intracellular systems. Oxidatively damaged bases (8-
hydroxydeoxyguanosine , thymine glycol, and thymidine glycol) have been measured 
in animal urine.  
 
1.6.5. APOPTOSIS PROTECTS SURROUNDING CELLS 
 
A fraction of cells exposed to high levels of oxidative stress will enter the apoptotic 
pathway. The mechanism of oxidative stress-induced apoptosis appears to involve 
loss of mitochondrial transmembrane potential (Zamzani, 1997), release of 
cytochrome c to the cytoplasm (Reed, 1997), loss of bcl-2 (Kane, 1993), 
downregulation and degradation of mitochondrially encoded mRNA, rRNA, and DNA 
(Crawford, 1998), and diminished transcription of the mitochondrial genome (Kristal, 
1994). Current thinking about toxicant-induced apoptosis suggests that, in 
multicellular organisms, the repair of severely damaged cells represents a major 
drain on available resources. To avoid this difficulty, it is suggested, individual cells 
within organisms (or organs or tissues) will “sacrifice” themselves for the common 
good of the many. Apoptotic cells are characterized by “blebbing,” nuclear 
condensation, and DNA laddering . Such cells are engulfed by phagocytes that 
prevent an immune reaction and recycle usable nutrients (Farber, 1990). Under high 
oxidative stress, some cells will simply disintegrate or become necrotic. 
Unfortunately, badly damaged cells that die by necrosis cause major immune and 
inflammatory responses, which may cause further damage to surrounding cells and 
tissues. Thus, for a tissue, organ, or organism, removing badly damaged cells by 
apoptosis represents a very real advantage (over necrosis) and should be 
considered as one of the “defense mechanisms”. Furthermore, over expression of 
the p53 gene has been seen to result in induction of multiple “redox-related” gene 
products, and initiation of apoptosis (Polyac, 1997). These observations support a 
strong involvement of oxidative stress mechanisms in general apoptotic pathways. 
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1.7. CELLULAR RESPONSE TO OXIDATIVE STRESS: SIGNALING 
FOR SUICIDE AND SURVIVAL 
 
At the cellular level, oxidant injury elicits a wide spectrum of responses ranging from 
proliferation to growth arrest, to senescence, to cell death. Typically, low doses of 
ROS, particularly hydrogen peroxide, are mitogenic and promote cell proliferation, 
while intermediate doses result in either temporary or permanent growth arrest, such 
as replicative senescence. Very severe oxidative stress ultimately causes cell death 
via either apoptotic or necrotic mechanisms. The particular outcome observed can 
vary significantly from one cell type to the next, as well as with respect to the agent 
examined, its dosage and/or duration of treatment. However, whatever the effect 
seen, it largely reflects the balance between a variety of intracellular stress signaling 
pathways that are activated in response to the oxidative insult. These pathways exert 
their phenotypic influences largely through modulation of transcription factor activities 
that effect changes in the pattern of gene expression. Some of the pathways are 
clearly linked to enhanced survival, while others are associated with cell death. 
 
1.7.1. PI3-KINASE/AKT PATHWAY 
 
Akt, also known as protein kinase B, is a serine/threonine kinase which plays a key 
role in integrating cellular responses to growth factors and other extracellular signals 
(Kandel and Hay, 1999; Meier and Hemmings, 1999). Akt is activated in response to 
these signals via a phosphoinositide 3-kinase (PI3K) pathway in which PI3K-
mediated generation of 3’-phosphorylated phosphoinositides leads to the recruitment 
of Akt to the cell membrane where it undergoes phosphorilation by kinases such as 
the 3’-phosphoinositide-dependent kinase-1 (PDK-1). Akt is an important anti-
apoptotic protein through which survival signals suppress cell death induced by 
growth factor withdrawal, cell cycle discordance, and detachment of cells from their 
extracellular matrix.  
Akt is activated in response to oxidant injury as well as several other stresses known 
to exert their cytotoxic effects in part through generation of ROS or perturbations in 
cellular redox status (Sonoda, 1999; Klotz, 2000; Wang, 2000; Huang, 2001). 
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Activation of Akt in response to oxidant exposure appears to be mediated largely 
through growth factor receptors. For example, activation of Akt by hydrogen peroxide 
can rely on the EGF receptor (Wang, 2000), on PDGF receptor (Klotz , 2000), or on 
Syk, a non-receptor protein tyrosine kinase (PTK), (Ding, 2000). Regardless of the 
particular receptor implicated in initiating the early events, all of the above mentioned 
studies demonstrated a requirement for PI3K in mediating the activation of Akt.  
Evidence suggesting that activation of PI3K/Akt signaling during the cellular response 
to oxidant injury was important for survival was initially obtained using the PI3K 
inhibitor Wortmannin. Treatment of cells with Wortmannin blocked activation of Akt 
by hydrogen peroxide and increased cell death (Sonoda, 1999). Direct support for 
the importance of this pathway in enhancing cell survival following oxidant injury was 
subsequently obtained in studies where Akt expression and activity were modulated 
using a genetic approach (Wang, 2000) showing to enhance survival of hydrogen 
peroxide-treated HeLa and NIH3T3 cells.  
The PI3K/Akt pathway is believed to transduce its survival signals through the 
phosphorilation-dependent suppression of intracellular apoptotic factors such as 
BAD, caspase 9, forkhead transcription factor, GSK3, and IKKa (Datta, 1991; Kandel 
and Hay, 1999). For the most part, there has been little evidence linking Akt-
dependent regulation of these factors to cell survival during oxidant injury; however, 
many studies, not only offer a mechanism for Akt’s protective influence during 
oxidant injury, but point to the existence of important avenues for cross talk between 
the PI3K/Akt and JNK signaling pathways. 
 
1.7.2. NUCLEAR FACTOR kB (NF-kB) SIGNALING 
 
The NF-kB family of transcription factors is composed of homodimers or 
heterodimers of Rel proteins that are involved in regulating a large number of genes 
related to immune function, inflammation, apoptosis, and cell proliferation (Pahl, 
1999). Since many of the treatments known to activate the transcription factor also 
lead to ROS production (e.g., cytokines and radiation), and antioxidants can 
effectively block NF-kB activation in response to such stimuli, ROS were once 
implicated as central mediators in the NF-kB activation process (Schmidt, 1996). 
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However, more recent studies have failed to provide support for this hypothesis, 
finding that (1) activation of NF-kB in response to hydrogen peroxide is cell type 
specific; (2) an increase in ROS is not required for NF-kB activation in many 
instances; and (3) antioxidants may inhibit NF-kB activity through mechanisms 
distinct from redox regulation. Nonetheless, in certain cell types, oxidative stress is a 
potent activator of NF-kB and this can have important consequences for cell survival. 
How do ROS activate NF-kB? The predominant mechanism by which NF-kB is 
activated by various stimuli is through the phosphorilation of IkB. IkB is an inhibitory 
protein that under normal conditions binds to NF-kB and sequesters it in the 
cytoplasm, thereby preventing its access to DNA. The phosphorilation of IkB results 
in its ubiquitination and degradation, freeing NF-kB to translocate to the nucleus and 
activate transcription through sequence-specific binding to DNA. For most inducers 
of NF-kB activation, IkB phosphorilation occurs on serine residues S32 and S36, and 
a number of different kinases have been reported to phosphorilate IkB on these sites. 
These include Ik-kinase (IKK), NF-kB-inducing kinase (NIK), double-stranded RNA-
activated serine-threonine protein kinase (PKR) (Schoonbroodt and Piette, 2000), 
and Akt (Madrid, 2001). Many of these kinases offer obvious points for cross talk with 
other signaling pathways known to be activated by oxidant injury.  
Virtually every step of the NF-kB signaling cascade is comprised of redox-sensitive 
proteins whose activities are modulated upon changes in ROS, some of these in a 
negative fashion (Schoonbroodt and Piette, 2000).  
A large number of NF-kB dependent genes have antiapoptotic functions. These 
include TNF receptor-associated factor 1 (TRAF1), TRAF2, cellular inhibitors of 
apoptosis proteins (CIAPs) ,MnSOD, and A20 zinc finger protein (Bours , 2000). 
NF-kB is also involved in regulating the expression of Bf1-1/A1 and Bcl-XL, two anti-
apoptotic members of the Bcl2 family. Accordingly, NF-kB expression has been 
shown to exert protective effects under various conditions. However, NF-kB activity 
has also been correlated with apoptosis and the activation of apoptosis-associated 
genes such as Fas ligand and p53 (Kasibhatla, 1999). Studies examining the 
influence of NF-kB on cell survival following oxidant injury have likewise produced 
mixed findings. Although some studies have provided evidence for a protective 
function of NF-kB in response to oxidative stress (Kim, 2001) more studies support 
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the notion that NF-kB exerts a pro-apoptotic effect following oxidant injury (Aoki, 
2001). In addition, the finding that p53-mediated cell death depends on NF-kB 
supports such a pro-apoptotic function (Ryan, 2000). Finally, it is worth noting that 
there are cases in which NF-kB has been shown to be activated in response to 
oxidant injury, but with no apparent influence on survival (Wang, 1998). 
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2. THESIS RATIONALE 
 
2.1. In silico structure of MGC14832 
 
The hypothetical product of c17-ORF37 gene, MGC14832 protein (also known as 
ORB3, XTP4 or C35) doesn’t show similarity with other known proteins, but it has 
anyway kept our attention for the characteristics emerging from the in silico structure 
predicted with Gene Scan/Gene Wyse analysis.  
Its sequences shows a total 89% homology with murine analogue as it is expressed 
in a region completely conserved (Katoh & Katoh, 2003); it is a 115 aa protein with a 
molecular weight of 12Kda, with a not-globular structure, high idrophylicy (18 Gln), 
and a putative complete intracellular structure. Besides, it presents many 
phosphorilation sites, PK cGMP, cAMP and Casein Kinase II dependent. Another 
relevant aspect is that it presents a putative CAAX box (CVIL) at its C-terminal, that 
is a farnesylation/geranylgeranylation site (prenylation site). This prenylation site is 
characteristic of many proteins involved in cell division (centromer associated 
proteins: CENP-E, CENP-F), and most of all it is essential for proto-oncogene Ras 
activation, witch deserves of being located in the internal surface of cytoplasmatic 
membrane to assert its mitogenic potential.  
Making a comparative analysis of MCG14832 protein structure 
(http://www.ncbi.nlm.nih.gov/BLAST) we saw that it is strictly associated with 
Selenium W-related protein: this is a family found in both bacteria and animals, 
including the animal proteins SelT, SelW, and SelH, all of which are selenoproteins. 
These proteins contain a domain with a CXXC motif near the N-terminus, where 
selenocysteine may replace the second Cys,  and levels of this selenoprotein are 
affected by selenium. The precise role of this family is unclear but it seems to be a 
protein family related with cell redox homeostasis. 
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3. AIM 
 
We don’t know yet if c17-ORF37 gene product is simply a by-product of HER2 
amplification or if this protein really exists and may contribute to clinical behaviour of 
HER2 positive tumours. We’ll try to know if the transcript from MGC14832 gene is 
only a by-product of HER2 amplification or if it is someway involved in tumour 
progression and resistance to therapy. 
Furthermore we’ll try to find a correlation with c17-ORF37 transcript and some 
cellular pathways to give c17-ORF37 a function and involvement in tumour 
progression, founding on the in silico structure of the protein. 
To understand this, it is necessary to acquire basic informations about transcript and 
protein expression on cancer cell lines, witch genetic aberration are highly 
representative of that occurring in primary tumours.  
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4. MATERIAL AND METHODS 
 
4.1. Cell lines  
 
SKBr3, BT 474: epithelial cells isolated and established from human breast cancer 
with HER2 amplification/overexpression. 
ZR75-1, MB MDA 231: epithelial cell isolated and established from human breast 
cancer without HER2 amplification/overexpression. 
All these cells are a  kind gift of Dott. Michele Milella (Istituto Regina Elena, Roma). 
293: human embryo kidney cell line, especially suggested for transformation study 
(kind gift of Dr. A. Houghton, Memorial Sloan Kettering Cancer Center).  
These cell lines were all maintained in Dulbecco’s modified Eagles medium (D-MEM) 
(Cambrex) supplemented with 10% foetal bovine serum (FBS) (Cambrex) and 0.5% 
penicillin/streptomycin.  
NIH3T3: murine fibroblast cell line purchased from ATCC (American Type Culture 
Collection)  were maintained in D-MEM supplemented with 10% calf serum (CS) 
(Cambrex) and 0.5% penicillin/streptomycin. 
T9-4: murine fibroblast cell line derived from NIH3T3 with established transfection for 
the human oncogene HER2.  
T19-7: murine fibroblast cell line derived from NIH3T3 with established transfection 
for the chimeric protein bearing the extracellular domain of human EGFR and the 
intracellular domain of  human  HER2. 
They were maintained in D-MEM supplemented with 10% FBS (Cambrex) and 0.5% 
penicillin/streptomycin, and are a  kind gift of Dott. Oreste Segatto (Istituto Regina 
Elena) 
All these cell lines were maintained at 37°C in a humidified 5% CO2 environment . 
 
4.2. RNA extraction 
 
Total RNA was isolated from cell lines with Nucleospin RNA II (Macherey Nagel) 
following manufacturer instruction witch included a treatment with RNase Free 
DNase I directly in column.  
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RNA yield was determined spectrophotometrically by measuring absorbance at 
260nm and RNA integrity was confirmed by electrophoresis on a 1.2% agarose gel. 
 
4.3. Quantitative Real Time PCR 
 
Total RNA from cell lines, were used to measure total c17-ORF37 transcript. RNA 
were reverse transcribed using reagents supplied in RevertAid® H Minus First Strand 
cDNA Synthesis kit. 1μg of total RNA was denatured for 5 minutes at 70°C, followed 
by chilling on ice for 1 minute. The denatured RNA was incubated for 1 hour at 42°C 
in 20μl of a reaction mixture containing: 2μl of 10X RT buffer, 0.5 μg/μl of Oligo dT 
primers, 10mM dNTPs mix, 40 units Rnase inhibitor and 200 units of reverse 
trascriptase. Reactions were heated to 70°C for 10 minutes to inactivate the enzyme 
and then chilled on ice. 
 
The PCR reaction was monitored in a MX3000P Personal Quantitative PCR System 
(Stratagene) using a Syber Green Fluorescent Master Mix (Stratagene). We used 
two couples of primers for c17-ORF37 detection on mouse samples and other two for 
detection on human ones: the first couple of primers was specific for mouse or 
human c17-ORF37 mRNA sequence, respectively, and the other couple was specific 
for the housekeeping gene β-actin (mouse) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), (human), used to normalize the expression level of c17-
ORF37 gene.  
 
Primers sequences are listed below: 
Mouse: 
mORF37 Fw: ATGAGTGGGGAGCCAGCG  
mORF37 Rev: TCACAGGATGACACAGGGAGG 
β-actin Fw: TTCGTTGCCGGTCCACA 
β-actin Rev: ACCAGCGCAGCGATATCG 
Human: 
hORF37 Fw: ACAGGTGCCTTTGAGATAGAGATAA 
hORF37 Rev: CTGTTGGTGATCTTTTCTAGGGTTT 
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GAPDH Fw: CAACAGCGACACCCACTCCT 
GAPDH Rev: AGGCCATGTGGGCCATGA 
 
Two different PCR cycles were used for mouse and human samples respectively, 
optimized to have 85-115% efficiency for each sets of primers. 
PCR programs consisted of a hot start at 95°C for 10 minutes, followed by 35 cycles 
of denaturation at 95°C for 1 min, annealing at 62°C (for mouse samples) or at 63°C 
(for human samples) for 1 minute, and elongation at 72°C for 1 min. The program 
ends with a melting curve witch consist of a rapid renaturation at 45°C and a slow 
denaturation until 95°C in witch the fluorescence is read continuously to detect the 
melting point of eventually different double stranded DNA amplified. With this method 
we were able to verify that both the reaction amplified only a single fragment of DNA. 
All PCR amplifications were performed in triplicate samples.  
Quantitative analysis of data was performed using the Mx Software and values from 
positive or treated cell lines or tissue were calibrated on the expression level of 
negative or control samples. Results shown are an average of at least three different 
experiments. 
 
4.4. Preparation of a mouse c17-ORF37 transcript probe for 
Northern Blotting 
 
1μg of total RNA from a mouse cell line (T9-4) was reverse transcribed using the 
RevertAid® H Minus First Strand cDNA Synthesis kit. The entire 350 bp sequence of 
mouse c17-ORF 37 was amplified by PCR using the following primers: 
 
Sense: ATGAGTGGGGAGCCAGCG  
Antisense: TCACAGGATGACACAGGGAGG 
 
PCR was performed with a denaturation at 95°C for 10 min followed by 35 cycles at 
95ºC for 1 min, 62ºC for 1 min, 72ºC for 1 min, with a final cycle at 72ºC for 10 min.  
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PCR products were purified using Nucleospin Extract II (Macherey Nagel) and cloned 
into pGEM-T Easy vector (Promega) using standard techniques to create pGEM-
mORF37. 
Murine c17-ORF37 sense and antisense digoxigenin-labeled RNA probes were 
generated from pGEM-mORF37. Briefly, the plasmid was linearized with either NcoI 
(antisense) or SalI (sense) and purified with the Nucleospin Extract II (Macherey 
Nagel). Plasmid (1μg) was incubated for 5 hours at 37°C with 10X transcription buffer 
(Roche Applied Science), digoxigenin-labeled nucleotide mix, 40 units/μl RNAsi 
inhibitor, and SP6 or T7 RNA polymerase (Roche Applied Science), respectively. The 
RNA probes were precipitated overnight at -20°C in 60μl 100% EtOH, 2μl 4M LiCl, 
2μl 200mM EDTA, centrifuged at 12.000 x g for 15 minutes at 4°C and resuspended 
in DEPC H2O. Colorimetric analysis was then performed to estimate the probe yield. 
 
4.5. Northern Blotting analysis 
 
Total RNA (10μg), purified as described above, were separated on a denaturing 
1.2% agarose gel containing 1X MOPS and 6.7% formaldehyde. The gel was 
washed for 10 minutes in 20X SSC to remove the formaldehyde before transfer to a 
Nytran Plus membrane (Schleicher and Schuell).  
To immobilize the RNA, the nylon membrane was subsequently exposed to UV ray 
for 1min 30 sec. Pre-hybridisation of the membrane was performed in DIG-Easy-Hyb 
buffer (Roche Applied Science) at 63°C for 1 hour. For the hybridisation, 10 ml of 
DIG-Easy-Hyb, to which had been added the DIG-labeled RNA probes (100 ng/ml) or 
β-actin probe (30 ng/ml; Roche Applied Science), were used per 100 cm2 of 
membrane. The hybridization was occurred at 63°C for 16 hours.  
The membrane was washed twice with 2X SSC / 0.1% SDS for 5 minutes and twice 
with 0.1X SSC / 0.1% SDS for 15 minutes at 63°C. The membrane was washed with 
Buffer 1 (100 mM Maleic acid, 150 mM NaCl, pH 7.5) for 5 minutes at room 
temperature.  
To detect the RNA-RNA hybrid, the membrane was preincubated for 45 minutes in 
blocking solution (Buffer 1 + 1% (w/v) casein) at room temperature and then 
incubated for 30 minutes with anti-DIG-antibody AP conjugate (Roche Applied 
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Science) diluted 1:10.000. A 2 x 15 minutes washing step in Buffer 1 was followed by 
equilibration in detection buffer (100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM 
MgCl2) for 5 minutes. Detection was performed with CSPD (Roche Applied Science). 
Finally, the membrane was exposed on Lumi-film chemiluminescent detection film 
(Roche Applied Science) for 2 hours or overnight. 
 
4.6. Cell lysates 
 
Cultured cells were collected by low-speed centrifugation at room temperature for 5 
minutes. After removal of culture media, the cell pellet was washed twice with cold 
PBS. Whole lysates were prepared by incubating 107 cells per ml Ripa buffer (25mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na deoxicolate, 0.1% SDS, 100 
μg/ml phenylmethylsulfonyl flouride PMSF, 1mM Na-Vanadate, 2μg/ml aprotinin, 
1μg/ml leupeptin and 1μg/ml pepstatin) for 30 minutes on ice. Lysates were cleared 
by centrifugation at 12.000 x g for 10 minutes at 4°C. The supernatant fluid was 
transferred to a new microfuge tube and the pellet was discarded. Protein 
concentration was determined by Bradford protein assay (Biorad). 
 
4.7. recORF37 recombinant protein: Gateway Cloning Technology  
 
Gateway Cloning Technology (Invitrogen) is a powerful methodology that facilitates 
protein expression. Using this technique it is possible to transfer DNA segments 
between vectors. In the first reaction (the BP reaction) a PCR product flanked by AttB 
recombinant sites is cloned into a Donor Vector to produce an “Entry Clone” in witch 
the gene of interest became flanked by an AttL site. In the second step, the LR 
reaction, the Entry Clone undergoes recombination via the AttL sites with a 
Destination Vector to create an Expression Clone. 
Murine c17-ORF37 DNA sequence was amplified from pGEM-mORF37. PCR 
program was performed as described above. 
Primers used were: 
 
attB1Fw:GGGGACAAGTTTGTACAAAAAAGC AGGCTTGAGTGGGGAGCCAGCG 
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attB2Rev:GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACAGGATGACACAGG
GAGG 
 
Using these primers we obtained a PCR product flanked by attB recombination sites 
to generate the mORF37 Entry Clone.  
The PCR product was purified using Nucleospin Extract II (Macherey Nagel).The BP 
Reaction was set up using pDonor201 Vector, BP Clonase Enzyme Mix, BP Reaction 
Buffer and AttB-PCR product,following manufacturer’s instruction, and was incubated 
for 3 hours at 25º. Proteinase K solution (37°C for 10 min) was added to stop the 
reaction.  
2 μl of BP Reaction was used to transform DH5α electro-competent cells and they 
were spread on LB agar + 50μg/ml Kanamycin plates. 
Entry Clone plasmids from spread colonies were extracted using GenElute Plasmid 
Mini Kit (Sigma) and screened for the presence of the insert by PCR using attL 
primers. 
 
AttL1:TCGCGTTAACGCTAGCATGGATCTC 
AttL2:GTAACATCAGAGATTTTGAGACAC 
 
The correct Entry clone was confirmed by sequencing using the mentioned attL 
primers, using manufacturer’s PCR program. 
An LR Reaction, was performed between the Entry Clone and a the Destination 
Vector pET-DEST17: LR Reaction Buffer, Entry Clone, Destination Vector and LR 
Clonase Enzyme Mix were incubated at 25°C for 3 hours. Proteinase K was added to 
stop the reaction. 1μl of the LR Reaction was used to transform BL21 Star (DE3) 
competent cells.  
This strain carries a mutated rne gene (rne131) which encodes a truncated RNase E 
enzyme that lacks the ability to degrade mRNA and this results in increased mRNA 
stability. These cells are also deficient in the outer membrane protease, that is 
important to reduce degradation of proteins expressed in the strains. 
Transformed BL21 Star were spread on LB agar + 50μg/ml Ampicillin. 
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The plasmid was extracted from colonies and checked by PCR screening using the 
mentioned above attB primers. 
 
4.8. Expression and purification of recORF37 recombinant protein 
 
The BL21 Star (DE3) E. Coli strains are chemically competent cells suitable for high 
level recombinant protein expression.  
Positive transformants were cultured in LB medium containing Ampicillin and growth 
at 37°C over night (mid log phase) and then diluted to allow the cells to return to 
logarithmic growth. The cells were induced for 3 hours with 0.3M NaCl since they 
reached mid-log phase (OD600= 0.5-1). Effectiveness of induction was confirmed by 
SDS PAGE and Comassie staining, with an equal amount of not inducted (NI) and 
inducted (I) cell lysates run on gel. A new protein band with the expected 
MW=12.000 appears on the “I” culture. 
Cell pellets from BL21 transformants were suspended in binding buffer (sodium 
phosphate buffer 20mM, NaCl 0.5M) pH=7.8, lysozyme (1mg/ml) was added and the 
suspension was incubated on ice for 30 min. After a 10 min incubation at 4°C, 
TritonX100 (1X final), DNase (5μg/ml) and RNase (5μg/ml) were added and lysates 
incubated for further 15 min. on ice. 
The suspension was centrifuged at 20.000 rpm for 20 min and the supernatant was 
filtered (0.45μm) before loading on the column. 
HiTrap Chelating HP, 1ml column (Amersham Biosciences) was used to purify 
recORF37 recombinant protein. Prior to use, the column was washed with 5 ml 
distilled water. 1ml of metal salt solution (0.1M NiSO4) in distilled water was loaded 
on the column. After these steps the column was washed again with distilled water. 
After column preparation, it was equilibrated by washing with 5-10 column volumes of 
binding buffer (0.02M sodium phosphate, 0.5M NaCl pH=7.8). The sample was 
applied using a pump and the flow rate was 1ml/min. After loading and washing with 
5-10 column volumes of binding buffer, recORF37 protein was eluted using a pH 
steps. 5 ml of phosphate buffer of each pH (ranging 7.8 to 4.0) was loaded on the 
column. A FPLC (Mono Q) column was used to further purify recORF37 protein using 
a phosphate buffer (0.02M, pH=7) and a NaCl gradient. 
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4.9. Mice and Rabbits immunization for anti-MGC14832 antibody 
production 
 
Mice or rabbits were immunized with pcDNA3.1 mORF37 (see chapter 4.15. for 
plasmid contruction) to obtain specific antibodies: in brief animals received a priming 
and two boosts with 100μg of plasmid in 100μl of saline, with intramuscular injection 
every 15 days. A week post the last boost blood was collected and sera were 
assayed for antibody production.  
In collaboration with Genesis Biotech Inc. (Taiwan) we immunized  rabbits to obtain  
anti-human or mouse c17-ORF37 antibody.  
Anti-human c17-ORF37 antibody were obtained immunizing animals, with a priming 
and two boosts subcutaneously,  with a synthetic peptide encompassing amminoacid 
4-22 from human sequence (4-EPGQTSVAPPPEEVEPGSG-22). Peptide was 
successfully synthesized, checked at mass spectrometry, and fused to KLH. Keyhole 
limpet hemocyanin (KLH) is a respiratory protein found in mollusks. Its large size 
makes it very immunogenic, and the large number of lysine residues available for 
conjugation make it very useful as a carrier for haptens. The phylogenic separation 
between mammals and mollusks increases the immunogenicity and reduces the risk 
of cross-reactivity between antibodies against the KLH carrier and naturally occurring 
proteins in mammalian samples. 
Succinylated KLH was conjugated to the hapten, via cross-linking with carbodiimide 
between the newly introduced carboxyl groups of KLH and the amine groups of the 
hapten. Rabbits were immunized with a priming (using complete Freund’s adjuvant, 
1:1 ratio) a two boosts (using incomplete Freund’s adjuivant, 1:1 ratio), 
subcutaneously at multiple sites, with 300 μg of the fused peptide. 
Anti-mouse c17-ORF37 antibody were obtained immunizing animals with a priming 
intrasplenic injection of 100 μg of pcDNA3.1 mORF37 as described (Velikovsky, 
2000), and boosting with subcutaneous injection of the recombinant protein 
recORF37 (300 μg, 1:1 ratio with complete and incomplete Freund’s adjuvant).  
Sera were collected from the immunized animals and affinity purified with a Protein A 
sepharose column (Amersham). The same procedure was followed with the pre-
immunization sera. 
 35
4.10. Hens immunization and IgY isolation from egg yolk 
 
To produce antibodies raised against the putative protein MGC14832, laying hens, 
obtained from a local egg farm, were injected subcutaneously  at multiple sites with 
300 μg of recORF37 using complete Freund’s adjuvant at first injection an incomplete 
Freund’s adjuvant for following injection (1:1 ratio), at days 1, 14 and 21. When a 
suitable number of eggs had been collected IgY antibodies were extracted from the 
yolk according to Concetti, 1994. Briefly, yolks were separated from the whites and 
broken in 4 volumes of 10mM phosphate buffer pH=7.5, containing 0.1 M NaCl. After 
stirring PEG 6000 powder (Sigma) was slowly added at a final concentration of 3.5%. 
The precipitate obtained was discarded after centrifugation at 17.000 rpm for 10 min 
and supernatant made 12% PEG. The proteins, pelleted at 17.000 rpm and 
redissolved in 15mM phosphate buffer pH=8, were further purified using a DEAE 
chromatography column and eluted in the same buffer plus 0.3M NaCl. The same 
procedure was followed for some egg collected before injection, from witch we 
obtained pre-immune IgY. Protein concentration was determined by Bradford protein 
assay (Biorad). 
 
4.11. Western Blotting analysis 
 
Electrophoretic assays of cell lysates or recombinant protein were performed using 
the Bio-Rad electrophoretic system. Protein samples in loading buffer were heated at 
100°C for 5 minutes and loaded on 15% SDS-PAGE. After electrophoresis and 
electro-transfer, the nitrocellulose membrane (PROTRAN Schleicher & Schuell) was 
blocked with 1% non fat-dry milk (Bio-Rad) in TBS-T for 1 hour. The membranes 
were probed with selected antibodies or animal sera for 1 hour at 37°C or overnight 
at 4°C. Bound antibodies were detected using appropriate secondary HRP-
conjugated antibodies (Calbiochem) for 1 hour at 37°C or overnight at 4°C, and 
visualized with a commercial ECL kit (Amersham). 
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4.12. ELISA 
 
ELISAs were performed according to standard protocols. In brief, recombinant 
protein (100 ng/well) was coated in a 96 wells plates in carbonate buffer pH 9.6 for 1 
hour at 37°C. After incubation with primary antibodies or antisera (indicated dilution) 
for 1 hour at 37°C and reaction with HRP-conjugated secondary antibody (1:3000) for 
1 hour at 37°C, 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) 
(Sigma), was added as substrate, and the developed color read at 405 nm. 
 
4.13. EMSA (electrophoretic mobility shift assay) 
 
Nuclear extracts are prepared as described (Zhou, 2000) with some modifications: in 
brief cells were lysed gently in a NP-40 containing sucrose buffer, while the nuclei 
remain intact. After a washing step they were resuspended in an ipotonic low salt 
buffer: the nuclei swell. Then a high salt buffer was added slowly: the nucleoplasm 
was extracted into the buffer. The extract was separated from nuclear envelope and 
DNA by centrifugation. 
To asses NF-kB activation 5μg of nuclear extract were run on a 6% non denaturing 
PA (O.5x TBE) gel, at 100V, together with NF-kB binding site double stranded biotin-
labeled or cold DNA (customized from Operon): 
 
NF-kB sense: AGTTGAGGGGACTTTCCCAGGC 
NF-kB antisense:GCCTGGGAAAGTCCCCTCAACT 
 
Run transfer and detection followed manufactures instruction of LightShift 
Chemiluminescent EMSA Kit (Pierce). Reactions to be performed include a negative 
control with no protein extraction for DNA to bind: no shift is observed and it 
establishes the position of unshifted probe band. The experimental samples, and the 
experimental samples with 200-fold unlabeled DNA were run to demonstrate that the 
shifted signal can be prevented by competition, and that the shift results from specific 
protein-DNA interaction.  
A supershift band is obtained running samples  with anti p50 or p65 NF-kB antibody 
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(Santa Cruz): specific antibody bound to NF-kB-DNA complex causes a further delay 
in DNA run.  
 
4.14. Cell treatment with PI3K inhibitors 
 
Cells were plated at 5 ⋅105 cells/well in complete medium in a 6 wells plate and let to 
adhere over-night. The following day medium was changed in medium without serum 
(starvation medium) and PI3K inhibitors were added at the following concentrations: 
Wortmannin (Sigma), 100nM, Gö6976 (Calbiochem), 10μM, Ly294-002 
(Calbiochem), 100nM. Cells were incubated at 37°C in a CO2 incubator for 24h and 
then harvested for RNA extraction, cDNA transcription and quantitative Real Time 
c17-ORF37 transcript quantitation. 
 
4.15. Stable transfection of NIH3T3 with murine c17-ORF37 
 
pcDNA3.1 (Invitrogen) has been chosen as the expression vector for stable 
transfection of NIH3T3 with the entire sequence of mouse c17-ORF37, as it carries 
the neo gene, responsible of antibiotic resistance to the selective antibiotic geneticin. 
pcDNA3.1 without the insert was included as negative control of transfected cells. 
For the generation of the plasmid mORF37 was first amplified with a couple of 
primers flanked by EcoRI and HindIII digestion sites, using pGEM-mORF37 as a 
template. 
 
HindIII Fw: GCATAAGCTTACCATGAGTGGGGAGCCAGCG 
EcoRI Rev: GGTGGAATTCTCACAGGATGACACAGGGAGG 
 
The amplified product was digested with HindIII and EcoRI and cloned into the 
HindIII-EcoRI cloning sites of pcDNA3.1 vector. 
Plasmid was linearized with the restriction enzyme BglII, to favourite integration, and 
purified with Nucleospin Extract II (Macherey Nagel) kit; concentration of DNA was 
determined spectrophotometrically by measuring absorbance at 260 nm, and if 
necessary brought to the final concentration of 1μg/μl. 
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NIH 3T3 cells were cultured in normal growing medium. The day before transfection, 
they were trypsinized, counted and plated in 24 wells plates at 1.5 X 105 cells per 
well so that they are 90-95% confluent on the day of transfection. Cells were plated in 
0.5 ml of their normal growth medium containing serum and without antibiotics.  
For each well of cells to be transfected (one with pcDNA 3.1-mORF37 and another 
with the empty vector pcDNA3.1) 0.8 µg of DNA was diluted into 50µl of OPTI-MEM I 
Reduced Serum Medium (Invitrogen) without serum, and 2µl of LIPOFECTAMINE 
2000 (LF2000™) Reagent (Invitrogen) was diluted into 50µl OPTI-MEM I Medium 
and incubated for 5 min at room temperature. DNA and LF2000 were then mixed and 
incubated at room temperature for 20min to allow complexes to form. 
The DNA-LF2000 Reagent complexes (100µl) was added directly to each well, from 
witch growth medium had been removed and changed in medium without serum, and 
incubated at 37°C in a CO2 incubator for 4-5 h. Growth medium has been replaced 
after 4-5 h with complete medium. 24-48 hours post transfection cells were diluted 
1:20 in two 96 wells plates and selective antibiotic (Geneticin, Invitrogen) was added 
at a final concentration of 500μg/ml. Medium plus selector was changed every 3 days 
until it was possible to isolate single stable transfected clones.  
The clones isolated were tested by quantitative Real Time PCR for murine c17-
ORF37 expression using as calibrator NIH3T3 transfected with empty vector. 
 
4.16. Transient transfection of 293 with GFP-mORF37 
 
pVAX1 (Invitrogen) has been chosen as the expression vector for transient 
transfection of 293 with the entire sequence of mouse c17-ORF37 fused at its N-
terminus with green fluorescence protein (GFP) from the jellyfish Aecquorea Victoria. 
For the generation of the intermediate plasmid, GFP was first amplified with a couple 
of primers flanked by HindIII and BamHI digestion sites, using pGFP (Clontech), as a 
template. 
 
HindIII-GFP-Fw: GCATAAGCTTACCATGAGTAAAGGAGAAGAACTT 
BamHI-GFP- Rev: GGTGGGATCCTTTGTATAGTTCATCCAATGCC 
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The amplified product was digested with HindIII and BamHI and cloned into the 
HindIII-BamHI cloning sites of pVAX1 vector. The plasmid obtained was verified by 
sequencing. Murine c17-ORF37 was amplified with an oligo flanked by BamHI 
digestion site and EcoRI Rev (described above). 
 
BamHI Fw :GCATGGATCCAGTGGGGAGCCAGCGCCGGTG 
 
The amplified product was digested with BamHI and EcoRI and cloned in pVAX-GFP 
intermediate plasmid, to obtain the fusion product pVAX-GFP-mORF37. The plasmid 
was checked by sequencing. 
For transient transfection of 293, it was used the same protocol as for stable 
transfection of NIH3T3, scaling up volumes and quantity for a 6-wells plate following 
manufacturer instruction. Transfection was performed on cells grown on poly-lysined 
cover slip, on 6 wells plate, and 24h post transfection, they were analysed for fusion 
protein expression and subcellular localization on confocal laser microscope (Biorad 
MRC600).As a control for specific fusion protein localization, 293 cell line was 
transfected with pGFP plasmid, following the same protocol. 
 
4.17. MTT assay for cell proliferation/viability 
 
Cell were plated in 96 wells plates at the indicated number in quadruplicate and let to 
adhere over-night. The following day they were treated with appropriate chemicals 
and incubated at 37°C in a CO2 incubator for the indicated period of time. At the end 
of treatment 20μl of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] were added per well (final concentration: 0.5 mg/ml) and plates were 
incubated for further 2-3 h. Colour was developed after flicking and tapping the plate 
and cell disruption with 100 μl dimethyl sulfoxide (DMSO, Sigma) and read on a 
multiwell scanning spectrophotometer (ELISA reader) at 540 nm. Data reported are 
an average of at least 3 different experiments. 
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4.18. Cytotoxicity Assay for cell necrosis 
 
With MTT assay we are only able to measure viable cells, but we are not able to 
distinguish between apoptotic or necrotic ones. At this purpose we measured lactate 
dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis, in 
supernatant medium of treated cells; assay was performed by Citotox 96-Non 
radioactive Cytotoxicity Assay (Promega). The test consists in a coupled enzymatic 
assay witch results in the conversion of a tetrazolium salt (INT) into a red formazan 
product. In brief cells were treated as described above; at the end of treatment 96 
wells plate was centrifuged at 1600 rpm for 5 min., and 50 μl of supernatant were 
transferred to a new 96 wells enzymatic (ELISA) plate. 50 μl of Substrate solution 
were added and plate was incubated 30 min. in the dark. 50 μl of stop solution were 
subsequently added and colour formed was read at 490 nm on a multiwell scanning 
spectrophotometer (ELISA reader). Cells from the previously centrifuged plate were 
tested for they overall viability with described MTT assay. 
Necrotic cells (experimental value) were counted as a percentage on spontaneous 
LDH release (not treated cells) and maximum release, obtained lysing the cell with a 
0,8% (final concentration) solution of Triton X-100 for 45 min.  
 
Necrosis
Max
SpontExp %100 =⋅−  
 
4.19. Peroxidase activity assays  
 
In order to asses if recORF37 purified recombinant protein, and/or mORF37 
transfected cells possesses a peroxidase activity we performed a series of 
peroxidase activity assays. Transfected and control NIH 3T3 were lysed by multiple 
freeze and thawing in H2O in order to maintain the proteins intact at a concentration 
of 107 cells/ ml . 
Catalase like assay:  
This method is based simply on the measurement of the loss of absorbance at 240 
nm of eventually metabolised H2O2. 
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Chemiluminescent assay:  
Chemiluminescent measurements were performed on Automat Berthold LB 953 
(Berthold Co. ,Wilbard, Germany). Assay was performed at different concentrations 
of purified recombinant protein or cell lysates in a final volume of 1 ml of PBS 
containing 100 μM luminol. Reaction started after injection of 50 μl of H2O2 (22mM 
final concentration). Measurement was followed for 40 sec. and area was calculated 
as photon per second (cps). 
Glutathione dependent peroxidase assay: 
This method measures glutathione  (GSH) oxidation degree by H2O2, catalysed from 
glutathione peroxidase (GSH-Px). This substrate is maintained constant adding 
glutathione reductase (GSSG-R) and NADPH, witch immediately convert each 
molecule of oxidised glutathione (GSSG) in its reduced form oxidising NADPH to 
NADP: 
 
Reduced glutathione formation (GSSG) is measured following the loss of 
absorbance, at 340 nm, of NADP. 
 
4.20. Höechst 33258 nuclear staining 
 
After H2O2 treatment (300 μM for 2 h) transfected NIH3T3 were washed two times 
with PBS, and fixed with 4% paraformaldehyde for 10 min. at room temperature, 
washed  with PBS and incubated with 10 μg/ml Hoechst 33258 (Sigma), for 10 min in 
the dark. Nuclear morphology was observed under fluorescent microscope (Olympus 
AX80). 
 
4.21. JC-1 staining for mitochondrial potential 
 
NIH3T3 transfected for mORF37 or not, were treated with 300 μM H2O2 for 2 h in 
2 GSH+ H2O2       GSH-Px         H2O+GSSG   GSSG-R        2GSH 
 
NADPH     NADP 
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starvation medium. After treatment serum was added to the cells to reach 1% final 
concentration. JC-1 (Invitrogen) was added at a final concentration of 10 μg/ml, 
mixed thoroughly to avoid coloured aggregate formation, and incubated for 30 min. at 
37°C. Cells have been washed two times in PBS and observed under fluorescent 
microscope (Olympus AX80), to detect mitochondrial depolarisation (increase in 
green/red fluorescence intensity ratio) that indicates early stages of apoptosis. 
 
4.22. Apoptosis detection by Annexin V 
 
Transfected NIH3T3 were treated with 50 μM H2O2 for 6h in medium without serum, 
then were trypsinized, and  washed two times with PBS. 3·105 cells from treated or 
untreated control cells were resuspended in 195 μl binding buffer (10mM 
HEPES/NaOH, pH=7,4, 140 mM NaCl, 2,5 mM CaCl2 ). 5 μl Annexin V (Alexis) were 
added to each sample for 10 min. at room temperature in the dark. Cells were then 
washed and analysed by flow cytometry (Becton Dickinson). 
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5. RESULTS 
 
5.1. c17-ORF 37 transcript correlates with HER2 amplification 
 
To evaluate a possible correlation between c17-ORF37 transcript and either HER2 
gene amplification or HER2 protein expression, we performed a quantitative Real 
Time PCR using a c-DNA from human breast cancer cell lines with different HER2 
status. Both BT474 and SKBr3 present HER2 amplification with the former having a 
higher estimated HER2 gene copy number than SKBr3 (16 copy vs. 32, Tomasetto, 
1995) but with HER2 protein inversely overexpressed (Tomasetto, 1995 and fig.1). 
MB MDA 231 and ZR 75-1 were chosen as breast control tumour cells with no HER2 
gene amplification and with basal protein expression (fig.1).  
Real Time PCR results reported in fig.2, show that the level of c17-ORF37 transcript 
correlates more tightly with HER2 amplification than with protein overexpression. The 
same association was found when cells had been kept in starvation (serum free 
medium) (fig.3).  
These results are in accordance with previous work, (Kauraniemi, 2003) that shows, 
by Real Time PCR analysis, an increase in the number of c17-ORF 37 transcript on 
frozen tumour tissues with HER2 amplification. 
 
5.2. Antibody production against MGC14832 
 
In order to detect the c17-ORF37 gene product, MGC14832 protein, we needed a 
suitable tool such as specific anti-MGC14832 antibodies, that we tried to produce, in 
our laboratory and in collaboration with Genesis Biotech Inc. (Taiwan). In spite of the 
very different approaches used, we had difficulties in breaking the immunotolerance 
in our models, probably because this hypothetical protein is largely conserved among 
various animal species (Katoh & Katoh,  2003).  
As described in Materials and Methods, we prepared a full-length mouse c17-
ORF37, eukaryotic expression vector, for DNA immunization, which failed to give an 
antibody response both in mice and rabbits (data not shown).  
In second instance, by using Gateway Cloning Technology (Invitrogen), we produced 
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and purified the entire mouse recombinant protein (named recORF37) (fig.4). 
In collaboration with Genesis Biotech Inc. (Taiwan) we used recORF37 to immunize 
rabbits: in brief  rabbits were first primed with the full-length mouse c17-ORF37 
eukaryotic expression vector, by intrasplenic injection, thought to induce a quicker 
response producing a larger number of B activated clones, then boosted 
subcutaneously with the recombinant protein as described in Materials and Methods.  
Antisera were collected and the affinity purified antibody (named GA427) was found 
to react against the recombinant protein both in Western Blotting and in ELISA at 
very high dilutions (fig.5-6), but was unable to reveal specific signals either on mouse 
or on human cell lysates, supposed to contain the expressed c17-ORF37 protein.  
To overcome the obstacle of the close homology of MGC14832, between mouse, rat 
and human, we decided to use laying hens as host for eliciting anti-MGC14832 
antibodies, since birds are known to give good immunoresponse to mammalian 
antigens. 
Chickens were then immunized with the recombinant protein as described in 
Materials and Methods, and total IgYs obtained from egg yolk were tested for the 
reaction against the same protein. Chicken antibodies worked well both in Western 
Blot and in ELISA with the recombinant protein at very high dilutions (fig.7-8), but 
again no specific signals were detected on cell lysates. 
In order to overcome immunotolerance and to enhance the specificity of the antibody 
to be produced, researchers from Genesis Biotech Inc. (Taiwan) synthesize the 
peptide encompassing the amminoacidic sequence 4-22 of human c17-ORF37, as 
this protein portion shares no similarity with any other protein in human proteome, 
(Table A). 
Peptide 4-22 was successfully synthesized, its sequence verified by mass 
spectrometry, and this epitope fused with KLH (Keyhole limpet hemocyanin) by 
standards method, and finally injected in rabbits following the schedule reported in 
Materials and Methods. The affinity purified polyclonal antibody obtained (named 
GA486) was able to detect the human cognate peptide (fig.9).  
When this antibody was used in Western Blotting analysis against human breast 
cancer cells lysates (fig.10) we obtained a strong signal at the expected molecular 
weight of 12 KDa, not detected with preimmune serum. This antibody failed to react 
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with mouse cell lysates supposed to express murine c17-ORF37 (see further).  
We report for the first time on in vivo expression of MGC14832 protein, and show 
that the levels of the protein in the human tumour cell lines examined, parallel the 
mRNA quantities previously measured (fig.11). 
 
5.3. c17-ORF 37 transcript and HER2 overexpression in mouse 
model 
 
To better understand whether the relationship between HER2 protein overexpression 
and c17-ORF37 transcript levels was depending on gene amplification, we used 
mouse cells, as in mice HER2 and c17-ORF37 are located in a strictly conserved 
synthenic locus (Katoh & Katoh 2003), but are never amplified. 
To this purpose, we used T9-4, a NIH3T3 mouse fibroblast cell line, transfected with 
the human HER2 gene, which is then overexpressed in absence of gene 
amplification. 
By performing Northern Blotting analysis on these cells, we surprisingly found that 
c17-ORF37 mRNA is overexpressed in T9-4 cell line compared to parental cells, 
especially when they were maintained in starving medium, to indicate that the 
process is independent from external signals (growth factors, hormones etc) (fig.12). 
To confirm and quantify our observation we performed a quantitative Real Time PCR, 
using, as a control of the transfection, T19-7, a NIH3T3 cell line transfected with the 
chimeric gene coding for the extracellular domain of EGFR (HER1) and the 
intracellular domain of HER2: the resulting chimeric protein is unable to be activated 
in the absence of EGF, its proper ligand.  
We found the differential pattern of expression on c17-ORF37 transcript between T9-
4 and NIH 3T3, already observed in Northern Blotting, when cells were grown in 
starving medium. When cells were grown in complete medium total level of c17-
ORF37 transcript were comparable among the cell lines (fig.13). Furthermore, T19-7 
have the same basal level of c17-ORF37 transcript as NIH 3T3, excluding a role of 
the transfection per se, in the observed overexpression. 
In absence of external signals, NIH3T3 are no more able to transcribe for c17-
ORF37, while T9-4 maintain the same level of transcript, also in the absence of 
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serum.  
From these preliminary data it may be supposed that HER2 overexpression at 
protein level is sufficient for c17-ORF37 transactivation, independently on HER2 
amplification status, at least in this model, and independently on transfection itself. 
The lack of a suitable antibody did not allow the detection of murine c17-ORF37, at 
protein level. 
 
5.4. c17-ORF 37 transcript can be modulated in a mouse model with 
some PI3K inhibitors 
 
XTP4 is one of the c17-ORF37 protein alias (Gene Bank accession number: 
AF490253), reported to be the “human gene 4 transactivated by hepatitis B virus X 
antigen” (Liu, 2002, unpublished data, direct submission on NCBI).  
As the inflammatory hepatitis B antigen, a potent viral oncogene, is capable to 
activate a large set of genes through NF-kB activation, we asked ourself whether 
c17-ORF37 could be activated likewise, by HER2 induced NF-kB activation. 
As it is reported (Zhou, 2000), HER2 activates Akt and NF-kB without extracellular 
stimulation, and we confirmed, by Electromobility Shift Assay (EMSA), that NF-kB is 
activated on T9-4 cell line, in a constitutive manner due to HER2 overexpression, 
while in NIH3T3 cell line it is not (fig.14). From the data in fig.13 it is evident that c17-
ORF37, on T9-4 cell line, is constitutively expressed in a steady state fashion, as no 
changes from starving are observed. On the contrary, starving conditions strongly 
reduced c17-ORF37 expression on NIH3T3.  
Our attention focused on NF-kB, a nuclear factor activated under a series of stress 
conditions; it stimulates proliferation and blocks programmed cell death (apoptosis), 
in different cell types, including breast cancer. Activated NF-kB was detected 
predominantly in ER (estrogen receptor) negative vs ER positive breast cancer, and 
mostly in the subset of HER2 positive tumours (Biswas, 2004). NF-kB can activate 
several antiapoptotic genes (among this Bcl-2, Bcl-xL and c-FLIP) and can 
transactivate the cell cycle regulatory protein cyclin D1, witch causes increased 
phosphorilation of retinoblastoma protein, through PI3K/Akt activation (Biswas, 
2000), and Akt activation strongly correlates with HER2 expression (Zhou, 2000, and 
 47
fig.14). 
For all the reasons explained above, we tried to find out whether PI3K/NF-kB 
cascade could be involved in c17-ORF37 transactivation, using some of this 
pathway’s inhibitors.  
To this attempt we used some commercially available compounds: Wortmannin, an 
irreversible inhibitor of PI3K that doesn’t affect upstream signal events (PI4K is 
inhibited at a concentration 100-fold higher), Gö6976 an inhibitor of Ca++ dependent 
PKC, and Ly 294-002, another PI3K inhibitor that act on the ATP binding site of the 
enzyme, not affecting EGFR, PKC, or PI4K activity (fig.15). 
First of all, we treated T9-4 for 24h in starved medium, at the indicated concentration 
of inhibitors, and performed a quantitative Real Time PCR to evaluate changes in 
c17-ORF37 mRNA between treated and untreated cells. We found that both 
Wortmannin and Ly294-002 lead to a 60-70% decrease in the amount of c17-ORF37 
transcript, while no differences between control cells and Gö6976 treated ones, were 
present (fig.16). Thus, we suggest that, at least in this model of HER2 transfected 
cells, c17-ORF37 is transactivated by means of PI3K pathway, without involvement 
of PKC activation. 
On the basis of the above results, we went back to human tumour cells to investigate 
if and how PI3K pathway could be involved: none of the inhibitors, tested in mouse, 
affected the amount of c17-ORF37 transcript in human cells (fig.17). 
What we can infer from this data is that the genetics of the tumour cell is much more 
complex than that of mouse transfection model. The real association of c17-ORF37 
and HER2 protein expression, beyond gene amplification, remains to be evaluated.  
Because of such a genetic complexity of human cancer cells, we chose to work with 
murine c17-ORF37 transfected fibroblast with the aim to have a much simpler model, 
on witch to study expression and function of MGC14832 protein. 
 
5.5. NIH 3T3 transfection: “gain of function” 
 
We transfected NIH3T3 cell line with mouse c17-ORF37 cDNA, and obtained a 
stable transfectant as verified by quantitative Real Time PCR for the overexpression 
of c17-ORF37 mRNA (fig.18). Among the positive clones, n°7 was selected as 
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expressing the highest level of c17-ORF37 transcript. The lack of a suitable antibody 
did not allow to detect the expression of murine c17-ORF37 (mORF37), at protein 
level.  
To bypass this problem we transiently transfected 293 cell line with a vector encoding 
mouse c17-ORF37 protein fused at its N-terminus with the GFP (green fluorescent 
protein). 24h post transfection, cells, grown on polylysined cover slips, were fixed and 
checked at confocal laser microscopy, for protein expression and cellular localization.  
Microscopy images (fig.19) confirmed the expression of c17-ORF37 in the 
transfectants, and its intracytoplasmatic location as hypothesized from in silico 
structure. The distribution of fluorescence inside the cell appears in a well 
characterised fashion, and seems not to be casually widespread in the cytoplasm. It 
appears in a defined internal distribution, with a “donuts like” morphology, mostly 
perimembrane. In some cases the fluorescence is very intense, condensed in some 
“vesicle like” structure. We don’t know if what we observe is due to the real 
distribution of the protein in vivo, or if it is due to the not natural overloaded system.  
This last possibility was refused as fluorescence distribution in 293 cells transfected 
with pGFP plasmid, is casual and widespread in all the cell (fig.20). 
 
5.6. MGC14832 as a survival factor? 
 
As next step, utilizing the NIH3T3 mORF37 transfectant, we tried to find out some 
roles of the MGC14832 protein, moving from two major hypothesis: (I) one rising 
from our observation that the protein is transactivated via PI3K/NF-kB pathway, a 
pathway involved in cell survival and resistance to apoptosis to several extracellular 
injury, among which is the oxidative stress (Martindale, 2002); (II) the second one, 
rising from the in silico structure of MGC14832 which is supposed to be a Seleno-W 
related protein, belonging to a family of protein with peroxidase activity. 
With this premises in mind we performed H2O2 toxicity assays, treating the cells with 
serial dilution of H2O2, from 640 μM to 10 μM, for 6 and 24 hours. Transfected 
mORF37 NIH 3T3 cells showed an increase in the overall viability, with a EC50 
(effective concentration 50%) at 24 h of 250 μM, versus 80 μM of the empty vector 
transfected NIH 3T3 (fig.21-22, Table B ). 
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We extended this study to an other oxidative agent such as tert-butyl-hydroperoxide, 
(t-BOOH) a peroxide radical generator: also with this compound mORF37 transfected 
cells earn an advantage on survival having an EC50=250 μM versus 30 μM in the 
empty vector transfected cells (fig.23, Table B). 
From these data a potential role of c17-ORF37 as a survival factor is arising. 
To verify whether this advantage on cell survival against an exogenous oxidative 
stress was due to a peroxidase activity of the protein, we performed a series of 
enzymatic assays, both on the whole cell (transfected or not) not-denatured lysates, 
and on recORF37 recombinant protein. 
The assays included the detection of catalase like activity, glutathione like peroxidase 
activity, peroxidase activity coupled to luminol oxidation (see Material and Methods).  
None of the assays, summarized in Table B, gave positive results either on 
recombinant protein or on cell lysates.  
As regarding to the recombinant protein, it could be argued that recORF37, produced 
in bacteria, lacks of secondary modifications that occur after protein synthesis and 
which may be essential to its enzymatic activity. Alternatively, the protein could have 
lost its proper folding during the long process of purification. 
On the other hand, the large amount of other peroxidase (like catalase or glutathione 
peroxidase) might have hidden the possible activity due to mORF37, on cell lysates. 
So we can’t rule out  that MGC14832 is devoid of a peroxidase activity.  
However, we wanted to understand in witch manner mORF37 transfected cells 
acquired an advantage on cell survival: did the control cells die for necrosis or 
apoptosis? Is MGC14832 able to modify cell susceptibly to oxidative stress avoiding 
apoptosis?  
For the purpose, as an indicator of the loss of integrity of the cytoplasmatic 
membrane occurring during necrosis and not during apoptosis, we measured the 
LDH release from H2O2 treated cells (fig.24-25). The results show that necrosis is not 
present, at least at low concentrations or at the short time of treatment. At 6 h only a 
little percentage of cells undergoes necrosis. At 24 h, the percentage increases, but 
never reaches 100%, even at high concentration of H2O2 (320 or 640 μM). 
When all the cells are no more viable, as revealed by MTT assay, only half of control 
or 20% of mORF37 transfected cells are LDH releasing. The data suggest a 
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protective role on the pathways of events leading to necrosis.  
However, when the cells are treated with 80 μM H2O2 for 6 h, in which 60% of control 
cells, or 85% of mORF37 transfected ones are viable, necrosis is not observed, so it 
could be indirectly inferred a protective role of mORF37 also on the apoptotic 
pathway. 
In order to directly ascertain such a role on apoptosis induced by H2O2 we performed 
the following experiments: 
(I) nuclear staining with Höechst 33258 (fig.26-27), which reveals nuclear 
condensation and blebbing, as well as a decrease in nucleus/cytoplasm ratio in 
treated vs not treated control cells; these features are much less present in c17-
ORF37 transfected cells.  
(II) mitochondria functionality by JC-1, which is a cationic dye that exhibit potential-
dependent accumulation in mitochondria, indicated by a fluorescence emission shift 
from green to red. As a consequence of mitochondrial depolarisation a decrease in 
the red/green fluorescence intensity ratio, is evidenced. JC-1 is utilized for the 
detection of mitochondria depolarisation occurring in the early stages of apoptosis. In 
control H2O2 treated cells there is an evident shift from red to green mitochondrial 
staining, indicating apoptosis (fig.28 A-B). The phenomenon is clearly less stressed 
in mORF37 transfected cells (fig.28 C-D). 
(III) Apoptosis detection by Annexin V (data not shown) gave no clear results as the 
percentage of stained H2O2 treated cells is very low. It is instead very evident a 
change in cell morphology, in both transfected and control cells, and most of all, an 
increase in median fluorescence intensity in sham vector vs mORF37 transfected, 
H2O2  treated cells. 
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6. DISCUSSION 
 
Numerous studies have illustrated the amplification and overexpression of the HER2 
oncogene in human breast cancer and its association to poor clinical outcome, thus 
emphasizing its essential role in breast cancer pathogenesis. Because of the 
development of targeted therapy against HER2, and the possible role of HER2 as a 
predictor of chemotherapy treatment response, identification of factors that might 
modulate the clinical behaviour of HER2-amplified tumours has become increasingly 
important. Co-amplification and increased expression of several other genes 
adjacent to HER2 have been reported. These co-amplified and over-expressed 
genes might be likely candidates for factors that have an impact on the treatment 
responses observed in the HER2-amplified tumours. Among these, in a minimal 
common region of 280 Kbp, there is an open reading frame (c17-ORF37) coding for 
a hypothetical protein, called MGC14832. 
Quantitative Real Time PCR of c17-ORF37 transcript disclosed the association with 
HER2 amplification in a panel of breast cancer cell lines (BT474, SKBr3, MDA MB 
231 and ZR75-1) whose genetic aberrations are highly representative of those 
occurring in primary tumours. 
However, c17-ORF37 gene product has never been reported as an overexpressed 
protein in tumour cells or tissues, neither is known whether it has a specific function 
in malignant transformation and/or in cancer development. The lack of suitable 
antibody, did not allow researchers to investigate on the presence of c17-ORF37 
protein in malignant tissue.   
To answer these questions, we first of all aimed at producing a polyclonal antibody 
against the N-terminal portion of the hypothetical protein, a region sharing no 
homology with any other known polypeptides. Despite the high specificity of the 
immunogen peptide used, the elicited polyclonal antibody showed, when used in 
western blotting of tumour cell lysates, some cross-reactivities with other proteins, 
making impossible its application to immunohistochemistry studies.  
Nevertheless, it was an important tool to detect, for the first time, the presence of 
c17-ORF37 expression product in human breast cancer cells, as resulted from 
specific antibody reaction with a protein focusing at 12 KDa, the expected molecular 
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weight of MCG14832. Besides, the intensity of the staining in the different cell lysates 
followed the RNA levels measured by quantitative Real Time PCR.  
Though the isolated cell lines, as said above, are highly representative of the in vivo 
malignant cells, they do not cover all the differences in genetic and somatic features, 
as, for instance, those with HER2 overexpression without gene amplification.  
Actually, there is a large subset of tumours, the most difficult to treat because of their 
resistance to HerceptinTM   therapy, that overexpress HER2 at protein level, without 
genetic amplification, a characteristic not borne by any isolated tumour cell lines, at 
least to our availability. 
In order to study c17-ORF37 expression at RNA and protein level in a cell line with 
these features, we used as a model a mouse cell line transfected for HER2, taking 
advantage by the fact that in mice HER2 and c17-ORF37 are located in a strictly 
conserved synthenic locus (Katoh & Katoh, 2003), but gene amplification never 
occurs. 
Unexpectedly we found that murine c17-ORF37 can be transactivated, at RNA level, 
by HER2, probably via PI3K/NF-kB pathway, as suggested by the dramatically 
decrease of c17-ORF37 transcript levels, induced by some inhibitors of this pathway.  
It is well known that NF-kB is a nuclear factor activator that stimulates proliferation 
and blocks programmed cell death (apoptosis), in different cell types, including breast 
cancer, and that, among other functions, promotes transcription of genes acting as a 
survival factor. Furthermore its activation strongly correlates with HER2 expression 
(Zhou, 2000). 
In an attempt to find a role to c17-ORF37 gene product, knock-down experiments 
were performed by Dr. Kallioniemi’s group at the University of Tampere, Finland: 
silencing c17-ORF37 gene in human cell line, with a specific si-RNA didn’t cause 
grave modification to cell viability, morphology and overall metabolisms (personal 
communication). 
To the same purpose, we followed the opposite way, that is, we tempted “gain of 
function” experiments by transfecting mouse fibroblasts with mouse c17-ORF37 gene 
(mORF37), under the control of a strong promoter such as CMV.  
Transfected cells did not modify their morphology, neither changed overall viability or 
growth ability, in respect to control cells. 
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To test the hypothesis that the protein acts as a survival factor, as suggested by 
PI3K/NF-kB involvement, and calling to mind that MG14832 in silico structure 
predicts it to be a Seleno-protein (Seleno-proteins are a class of protein controlling 
the redox status of the cell), mORF37 transfected cells were submitted to an 
exogenous potent oxidative insult, such as the one given by H2O2. 
The results, while confirming that cells subjected to hexogen H2O2, die from both 
apoptosis and necrosis (Kannan, 2000; Mao, 2006), show that these cells acquired 
resistance capacity to this oxidative stress as evidenced by toxicity assay and by 
microscopic analysis. Nuclei from mORF37 transfected cells appeared less damaged 
in respect to control cells, as well as the mitochondrial potential less altered. These 
observations suggest the idea that MG14832 might exert its protection on apoptosis 
pathway, at least for short time exposition of the oxidant. 
To understand whether MG14832 exerts its protection by acting on either the 
apoptosis or necrosis pathway, or on both of them, we made some other 
experiments, like Annexin V binding. 
The data collected did not allow the answer: at least at low doses of H2O2, a weak 
Annexin V binding, both on transfected and control cells (data not shown), together 
with a change in cell morphology, was detected from FACS analysis.  
On one hand, this altered morphology may reflect the lost of selective membrane 
permeability and increased rigidity, as already reported for cells exposed to H2O2 
stress (Davies, 2000): this may account for the very low binding of Annexin V that 
would subtract to the detection, cells eventually engaged in apoptosis. However, the 
few positively stained cells showed a higher median fluorescence intensity in the 
control cells than in the transfected ones, possibly indicating the latter as less prone 
to apoptosis. On the other hand, the altered morphology of the cells could simply be 
an expression of the ongoing necrosis process, which is evidenced by the release of 
LDH when higher concentration of H2O2 were used for longer time.  
Data are then not explicative or conclusive about which pathway MG14832 might act 
on. Moreover, the possibility of an anti-apoptotic activity induced through dead factor 
receptors family (FAS, TNF) should be investigated. HER2 transfected mouse 
fibroblast are resistant to TNF-α  ( Zhou, 2000) via the Akt/NF-kB pathway, witch is 
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constitutively activated, so the involvement of MGC14832, that, from our results, 
seems to be activated from the same pathway, has to be taken into account. 
As regards the search for a specific enzymatic activity of MGC14832 that may 
explain the protection from peroxides, a set of experiments have been conducted to 
detect some peroxidase activities, as it might be supposed from its in silico structure. 
All the attempts made, failed, for the reasons hypothesized in the experimental 
section. 
By now we can only suppose MGC14832 as a survival factor, overexpressed by 
either gene amplification or by activated PI3K/NF-kB pathway, acting on both 
apoptosis and necrosis.  
From several lines of evidence, from both human cancer and animal models, 
Weinberg (Hanahan and Weinberg, 2000) proposed that few (six) alterations in cell 
physiology are essential to collectively dictate malignant transformation and growth, 
and that tumour development proceeds as a Darwinian evolutionary process in which 
a succession of genetic changes lead to a progressive conversion of normal cell into 
cancer cell. 
In the case of HER2 amplicon, there is a concomitant gain of pro-tumour functions, 
given from genes not only co-amplified, but also overexpressed (Kauraniemi, 2003): 
self sufficiency in growth signals (HER2), increased proliferation from hormone action 
(MLN64 facilitates steroid hormone production in cancer cells), (Akiyama, 1997), 
metastasis properties (GRB7 codes for a SH2 domain containing growth factor 
receptor tyrosine kinase that has a function in cell migration), (Shen, 2002) and, from 
our data, resistance to oxidative attack, probably through evasion from programmed 
cell death (MGC14832). Besides, this last function might be acquired together with 
HER2 overexpression even in the absence of gene amplification. 
What is the significance of the connection of HER2 overexpression, generated either 
from genetic or epigenetic, with MGC14832? Is it specific of c17-ORF37, or may it 
also concern some other genes of the amplicon? Is there some particular cellular 
program that links together HER2 and c17-ORF37 overexpression, irrespectively of 
their gene amplification, or vice versa they do not respond to the same program? 
Can we find from the answer to these questions an explanation on why HerceptinTM 
only works with amplified overexpressing HER2 tumours? 
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The finding that its expression is not strictly depending on the level of gene 
amplification, enforce the possibility that measuring MG14832 expression in HER2 
positive tumour tissues (amplified or not), may add information on the characteristics 
of the tumour itself, in term of both prognosis and therapeutic indication.  
There is a need for a monoclonal antibody that, in collaboration with Genesis Biotech 
Inc., is under production while this thesis is on printing, to detect MGC14832 on fresh 
or fixed breast cancer tissue, and eventually to make an array on the in vivo 
distribution of the protein. 
In addition, the monoclonal antibody may allow the isolation and purification of the 
protein in its native form, that could be essential to discover its enzymatic activity, if 
any.  
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7. FIGURES 
 
 
 
Fig.1: Western Blotting analysis. 50 μg of whole cell lysates were run on SDS PAGE. Proteins 
transferred to nitrocellulose membrane were incubated with C-18 (Santa Cruz), a polyclonal anti HER2 
antibody, and re-incubated after stripping with anti β-actin monoclonal antibody (Sigma). 
 
 
 
 
 
Fig.2 :Quantitative Real Time PCR. c17-ORF37 mRNA relative quantity on human cell lines with 
different HER2 status. Cells were grown in complete medium  
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Fig.3: Quantitative Real Time PCR. c17-ORF37 mRNA relative quantity on human cell lines with 
different HER2 status. Cells were grown in medium without serum (starving) . 
 
 
 
 
 
 
 
Fig.4: SDS-PAGE of recombinant protein recORF37. Induction, (first panel) and purification 
(second panel) of recORF37 recombinant protein . The band of induced culture (I) is strongly visible at 
12 Kda, while is absent in the not induced (NI) one. Protein was first purified by using an Hi-Trap 
Chelating column (Amersham), and then a Mono-Q column, in FPLC chromatography apparatus. 
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Fig.5: Western Blotting analysis . 3μg of recORF37 recombinant protein were run on SDS PAGE 
and proteins transferred to nitrocellulose membrane were incubated with indicated dilution of GA427, 
or preimmune rabbit sera. 
 
 
 
 
Fig.6: ELISA. 100ng of recORF37 recombinant protein were coated on the plate and incubated with 
the indicated dilution of GA427 or preimmune rabbit sera. 
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Fig.7: Western Blotting analysis. 3μg of recORF37 recombinant protein were run on SDS PAGE 
and proteins transferred to nitrocellulose membrane were incubated with indicated dilution of α-
recORF37 IgY, or preimmune IgY. 
 
 
Fig.8: ELISA. 100ng of recORF37 recombinant protein were coated on the plate and incubated with 
the indicated dilution of α-recORF37 IgY, or preimmune IgY. 
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 Table A: Human 4-22 Synthetic Peptide: The synthetic peptide encompassing the amminoacidic 
sequence 4-22 of Human MGC14832 is the protein portion sharing no similarity with any other human 
protein. 
 
 
 
 
 
 
 
 
 
 
Fig.9: Western Blotting analysis. 3μg of 4-22aa hORF37 epitope peptide (fused to KLH) were run 
on SDS PAGE. Proteins were transferred to nitrocellulose membrane and incubated (1:500) with 
GA486 polyclonal antibody or preimmune rabbit sera.  
 
 
 
1 EPGQTSVAPPPEEVEPGSG 19   synthetic peptide 
4 EPGQTSVAPPPEEVEPGSG 22   Homo Sapiens Identities = 19/19 (100%), Positives = 19/19 (100%), Gaps = 0/19 (0%) 
GA486              preimm. 
                       sera 
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Fig.10: Western Blotting analysis. 50 μg of whole cell lysates were run on SDS PAGE. Proteins 
transferred to nitrocellulose membrane were incubated with GA486, and re-incubated after stripping 
with anti β-actin monoclonal antibody (Sigma). 
 
Fig.11: Densitometric scan of WB bands. Bands from fig.10 were quantified by an imaging 
densitometer (GS-670, Biorad). Relative quantities of MGC14832, normalized to the housekeeping 
protein β-actin, were reported in respect to MDA MB 231, chosen as basally expressing cells. 
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Fig.12: Northern Blotting analysis. 15 μg of total RNA from T9-4 and NIH 3T3 (grown in complete or 
starving medium). Hybridisation was performed  at  63°C either with mORF37 or β-actin specific 
probes. 
 
 
Fig.13: Quantitative Real Time PCR. c17-ORF37 mRNA relative quantity on mouse cell line model. 
Cells were grown in complete medium or medium without serum (starving). Data were calibrated on 
NIH 3T3 grown in starving medium. (T9-4: HER2 transfected NIH3T3, T19-7:HER1/HER2 chimera 
transfected NIH3T3)  
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Fig.14 Electromobility shift assay (EMSA): 5 μg of nuclear proteins of starving cells. Run was 
performed with double stranded DNA corresponding to NF-kB binding site, with or without (cold DNA) 
biotinilation (Shift) and with antibodies against each NF-kB subunit (p50, p65) (Supershift). 
 
 
 
 
 
 
Fig. 15. HER2/PI3K/NF-kB pathway and inhibitors: 1) Wortmannin is an irreversible inhibitor of PI3K 
that doesn’t affect upstream signal events (PI4K is inhibited at a concentration 100-fold higher). 
2) Ly294-002 is a PI3K inhibitor that acts on the ATP binding site of the enzyme, not affecting EGFR, 
PKC, or PI4K activity.  
3) Go6976 is an inhibitor of Ca++ dependent PKC.   
 
 
 65
 
Fig 16: Quantitative Real Time PCR. c17-ORF37 mRNA relative quantity on mouse cell line model. 
Cells were treated for 24h in starving medium with Wortmannin (100nM) or Go6976 (10μM) or Ly294-
002 (100nM). c17-ORF37 transcript is calibrated vs untreated cells (C). 
 
 
Fig 17: Quantitative Real Time PCR. c17-ORF37 mRNA relative quantity on BT474 and SkBr3 
human cell lines. Cells were treated for 24h in starving medium with Wortmannin (100nM) or Go6976 
(10μM) or Ly294-002 (100nM). c17-ORF37 transcript is calibrated vs untreated cells (C). 
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Fig.18: Quantitative Real Time PCR. c17-ORF37 mRNA relative quantity of mORF37 transfected vs. 
empty vector transfected NIH 3T3. Cells were grown in medium without serum (starving).  
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Fig. 19: Confocal laser microscopy of GFP-mORF37 transfected cells.  The distribution of 
fluorescence inside the cell appears in a well characterised fashion, and seems not to be casually 
widespread in the cytoplasm.  It gives the idea of a clear internal distribution, with a “donuts like” 
morphology, mostly perimembrane (A: central optical section, B: z axis reconstruction). In some cases 
the fluorescence is very intense, condensed in some “vesicle like” structure (C: central optical section, 
D: z axis reconstruction). 
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Fig. 20: Confocal laser microscopy of pGFP transfected cells.  The distribution of the fluorescence 
is casual and widespread in all the cell. 
 
 
 
Fig.21: H2O2 MTT assay. 2x104 transfected NIH 3T3 were plated on a 96 wells plate and treated with 
H2O2 for 6h at the indicated dilutions. Viability was evaluated by MTT assay. 
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Fig.22: H2O2 toxicity assay. 2x104 transfected NIH 3T3 were plated on a 96 wells plate and treated 
H2O2 for 24h at the indicated dilution. Viability was evaluated by MTT assay. H2O2 effective dose at 
50% (EC50) was 250 or 80 μM for mORF37 transfected or sham vector transfected NIH 3T3, 
respectively. 
 
Fig.23: t-BOOH MTT assay. 2x104 transfected NIH 3T3 were plated on a 96 wells plate and treated 
with indicated dilution of tert-butyl-hydroperoxide, (t-BOOH ), for 24h. Viability was evaluated by MTT 
assay. t-BOOH effective dose at 50% (EC50) was 250 or 30 μM for mORF37 transfected or sham 
vector transfected NIH 3T3, respectively. 
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Table B: First panel: Summary of EC50 measured on transfected NIH 3T3 for both H2O2 and t-BOOH.  
Second panel: Peroxidase activity assays performed. All tests gave negative results, both on 
transfected cells and on recombinant protein, recORF37. 
 
 
 
Fig.24: H2O2 cytotoxicity assay. 2x104 transfected NIH 3T3 were plated on a 96 wells plate and 
treated with H2O2 for 6h at the indicated dilutions. Necrosis was evaluated on 50 μl of supernatant 
measuring LDH production. 
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Fig.25: H2O2 cytotoxicity assay. 2x104 transfected NIH 3T3 were plated on a 96 wells plate and 
treated with H2O2 for 24h at the indicated dilutions. Necrosis was evaluated on 50 μl of supernatant 
measuring LDH production . 
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Fig. 26: Hoechst 33258 staining of empty vector transfected cells. A: Sham vector transfected 
cells treated with 300 μM H2O2 for 2 h presents nuclear condensation (arrowheads), and blebbing 
(arrow), and a decrease in nucleus/cytoplasm ratio, in comparison with untreated cells (B). 
 
 
 
 
 
Fig. 27: Hoechst 33258 staining of mORF37 vector transfected cells. C: mORF37 vector 
transfected cells treated with 300 μM H2O2 for 2 h doesn’t presents nuclear condensation or blebbing, 
and nucleus/cytoplasm ratios is unaltered.  D: Untreated cells . 
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Fig. 28: JC-1 staining of control or mORF37 vector transfected cells.  Empty vector transfected 
cells treated (B) with 300 μM H2O2 for 2 h presents a great decrease in red/green fluorescence 
intensity ratio in respect to untreated cells (A). The phenomenon, indicating an early stage of 
apoptosis, is less stressed in mORF37 transfected cells (C: untreated, D: treated with 300 μM H2O2 for 
2 h ). 
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